



PASPCR Newsletter

Volume 3 Number 3

September, 1995

Introduction . . .

by the Publications Committee

The **PASPCR Newsletter** is published quarterly and is intended to serve as a means of communication for the members of our Society. As such, we invite our membership to actively contribute to the *Newsletter*; help us to update the Job Listings, Calendar of Events, Meeting Reports, Abstracts in press and other items of general membership interest. If you attend a scientific meeting at which you heard about work which you think will be of interest to the membership of the **PASPCR**, please write a few paragraphs summarizing what was presented and share it with us. If you should have a change of affiliation or address, we'd like to know that, too. This is your *Newsletter*, and we depend upon you to help us make sure it best serves the Society's needs. Contributions and comments can be sent to any of the members of the Publications Committee.

The Publications Committee wants to make collaboration between members of the Society as easy as possible and toward that goal we are encouraging the use of E-mail and other forms of electronic communications. We encourage everyone who has an E-mail address to forward it to the Publications Committee. The Publications Committee is willing to help any member of the **PASPCR** get you in touch with the individuals who can set up your E-mail account and to some extent will help you get started.

The **PASPCR** has a Gopher server that can be found from your home Gopher under "International Organizations" as "PanAmerican Society for Pigment Cell Research (PASPCR)". Here you have access to past **PASPCR** Newsletters, the current ByLaws and membership list. We are currently working with the IFPCS to develop a list of resources available to **PASPCR** members. This list will include cell lines, antibodies, coat color mutants and other items of interest to pigment researchers. If you have any other

IN THIS ISSUE

Introduction	p 1
PASPCR Contact Information	p 2
Calendar of Events	p 2
Welcome to New Members	p 3
Corporate Sponsors	p 3
1995 PASPCR Elections	p 3
1996 XVI th Intl Pigment Cell Conf	p 3
PASPCR Secretary/Treasurer's Report	p 4
Meeting Report - Photobiology	p 5
Members in the News	p 6
Positions Wanted / Available	p 6
INTERPIG Update	p 7
Bibliography	p 15

enclosure: IFPCS DataBase Form

ideas for items to be placed on Gopher, please contact someone on the Publications Committee.

**PanAmerican Society for
Pigment Cell Research**

c/o **Dr. Richard A. King**
Department of Medicine
University of Minnesota
516 Delaware St, SE
Minneapolis, MN 55455
FAX: (612) 624-6645

Officers

Vincent J. Hearing
President
Sally Frost-Mason
President-Elect
Richard A. King
Secretary/Treasurer

Council Members

Zalfa A. Abdel-Malek
Raymond E. Boissy
Murray H. Brilliant
Alan N. Houghton
Gert M. Jacobsohn
William S. Oetting
Seth J. Orlow
Dewayne Townsend
Walter C. Quevedo, Jr.

IFPCS Representative

James Nordlund
Past-President

The **PASPCR Newsletter** is published quarterly; for further information and/or to submit articles, contact the:

Publications Committee:

Dr. William S. Oetting (chair)

University of Minnesota
16-262 Moos Tower
515 Delaware St., S.E.
Minneapolis, MN 55455-0311
FAX: (612) 626-4027
E-mail: BILL@LENTI.MED.UMN.EDU

Dr. Alan N. Houghton

Memorial Sloan-Kettering Cancer Center
Chief, Clinical Immunology Service
1275 York Avenue
New York, NY 10021
FAX: (212) 717-3036

Dr. Walter C. Quevedo, Jr.

Brown University
Division of Biology and Medicine
Box G
Providence, RI 02912
FAX: (401) 863-1971

Calendar of Events :

Oct 19 - 21, 1995 6th Meeting of the European Society for Pigment Cell Research, to be held in Lausanne, Switzerland (contact: ESPCR '95, Centre Pluridisciplinaire d'Oncologie, CHUV-BH 06, CH-1011 Lausanne, Switzerland; FAX: +41 21/314-3957)

Oct 27-28, 1995 Photocarcinogenesis: Mechanisms, Models and Human Health Implications, to be held in Washington DC (contact: Skin Diseases Research & Education Found, 23550 Commerce Park Road, Suite 2, Beachwood, OH 44122; FAX: 216/831-6385)

Dec 2 - 3, 1995 Meeting of the Japanese Society for Pigment Cell Research, to be held in Osaka, Japan (contact: Prof. Toshiteru Morita, Dept of Biology, Osaka University, 560 Osaka, Japan; FAX: +81 6/850-5613)

Dec 9 - 13, 1995 Annual Meeting of the American Society for Cell Biology, to be held in Washington DC (contact: ASCB National Office, 9650 Rockville Pike, Bethesda, MD 20814-3992; FAX: 301/530-7139)

Oct 29- Nov 3, 1996 XVIth International Pigment Cell Conference, to be held in Anaheim, California, (contact: MMC/UCI Center for Health Education, PO Box 1428, Long Beach, CA 90801-1428, FAX: 310/933-2012)

Jun 15- 18, 1997 VIIth PASPCR Annual Meeting, to be held in Providence, RI (contact: Dr. Walter C Quevedo, Jr., Brown University, Division of Biology and Medicine, Providence, RI 02912; FAX: 401/863-1971)

Welcome to New Members**by Richard A King**

We welcome the following new members to the **PASPCR**

Edwart T. Borish	Ashok K. Chakraborty	David Hewett-Emmett
Won Hyoung Kang	Estela E. Medrano	Kyoung Chan Park
Mark V. Reedy	Michael Rachkovsky	Stefano Sodi

If anyone is interested in joining our Society or wishes to sponsor a member, application forms can be obtained from Dr. Richard King at the PASPCR Secretary/Treasurer's office.

Corporate Sponsors**by Richard A King**

The PASPCR would like to acknowledge and thank our Corporate Sponsors; the list below reflects contributions over the past 2 years. Financial gifts from these sponsors have allowed our Society to increase benefits to the membership far out of proportion to the actual dues collected from members. Monies contributed by these sponsors have been used over the years to support various PASPCR functions including our Young Investigator Award program, meeting travel stipends, annual meeting expenses and this Newsletter.

GOLD Corporate Patrons

ICN Pharmaceuticals, Inc
Lawrence M Gelb Research
Foundation of Clairol, Inc
Ortho Pharmaceutical Corp

SILVER Corporate Patrons

Avon Products, Inc
Chesebrough-Pond's USA Co
Procter and Gamble Co
Shiseido Co, Ltd

Corporate Patrons

Galderma Laboratories, Inc

1995 PASPCR Elections**by Richard A King**

The PASPCR will hold its annual elections at the end of this year. As announced at the General Business meeting held at the PASPCR Annual Meeting in Kansas City, the Nominations Committee has proposed a slate of candidates for the various open positions. We would like to remind the membership that additional names can be added to the ballot via the mechanism outlined in our ByLaws, i.e. by submitting a petition ballot signed by at least 5 active members of the Society and accompanied by a signed statement from the candidate that he/she is willing to run for that office. Such petition ballots must be delivered to the office of the Secretary/Treasurer (Dr. Richard King) no later than 2 months after the slate of candidates have been announced (i.e. by September 30, 1995). The Nominations Committee nominated several other individuals who have either declined to run or have not yet responded to an enquiry as to their interest in the position.

for President-Elect:	Richard A. King	
for Secretary/Treasurer:	James J. Nordlund	
for Council members:	Kenneth Mason	David A. Norris
	Robert J. Smyth	John D. Taylor

XVIth IPCC (International Pigment Cell Conference)**by Roger Bowers, Frank Meyskens**

The XVIth International Pigment Cell Conference will be held from October 29th to November 3rd, 1996 at the Disneyland Hotel in Anaheim, California. Frank Meyskens is the Organizer of this meeting

with Roger Bowers and Alistair Cochran serving as co-chairs of the Organizing Committee. More information regarding this meeting (and its interesting venue) will be forthcoming in future Newsletters and in separate mailings. Dr. Meyskens has asked that the following announcements be included in our Newsletter.

Satellite Conferences: No satellite conferences will be supported by the local organizing committee that are held within the time frame of the XVIth International Pigment Cell Conference, Tuesday, October 29, 1996; 6:00 pm to Sunday, November 3, 1996; 8:00 am. There are a wide number of venues possible to hold small or large satellite conferences either before or after the main pigment cell meeting. Our Memorial/UCI Educational Foundation will be happy to work with you in planning, for a small fee, and we request that we be notified of the intent of any satellite conference no later than June 1, 1995. If we are notified later than this date, accommodations and planning availability cannot be guaranteed.

Competitive Stipend for Travel Support: The Organizing Committee will provide funds in a competitive manner for graduate students, post-doctoral fellows and those within five years of formal academic appointment. The number of stipends will depend on the availability of funds and further information will become available during the second and subsequent informational mailings.

PASPCR Secretary / Treasurer's Report :

by Richard A King

Following is a synopsis of the PASPCR Council Meeting held by teleconference on April 20, 1995 . . .

Hearing opened the meeting, and a quorum was declared present. Minutes of the January 19, 1995, Council meeting were unanimously approved. Total dues collected for 1995 has been \$10,315.

The Nominating Committee for the 1995 election will include Frost-Mason, Chair, Jacobsohn, (Council member) and R. Bowers, B. Fuller and A. Castrucci (Members-at-Large). The initial report of nominations will be made at the June meeting. The membership brochure was still in development and King was requested to circulate the final draft to the council for approval.

Quevedo reviewed the arrangements for the 1997 meeting in Providence. The meeting will be held at the Westin Hotel. The room cost will be \$115 per room for single or double occupancy. The Program Committee will be formed soon and the organizers were asked to consider a theme for the meeting so that potential keynote speakers can be identified. D. Norris has tentatively agreed to host the 1998 meeting in Denver.

Under old business, the amendment to the Young Investigator Award Rule and Regulation was discussed. Concern of excluding individuals who give good presentations at the annual meeting were reviewed, and it was suggested that the final list of nominations for the 1995 meeting be reviewed at the Council meeting in Kansas City. The Council can then decide whether it would be appropriate to return to the original procedure of having an anonymous committee select any eligible young investigator who presents at the meeting. This was accepted by the Council.

Fourteen travel award requests have been received for 1995. All requests will be reviewed and letters of acceptance sent to all individuals who meet the criteria of eligibility.

Under new business, Hearing reviewed the previous Rule and Regulation for Honorary Membership. Previous discussions by the Council had not addressed the issue of whether or not an Honorary Member should still be an active researcher and a member of Society. The Membership Committee was asked to review the Rule and Regulation on Honorary Membership and to develop several options that could deal with this issue. Hearing reviewed a letter from Frank Meyskens requesting the names of 3-5 members who are doing exciting new research, and 3-5 members who could serve as exciting participatory chairs of sessions. A committee that would identify individuals for this request was formed.

The minutes have been prepared by R. King, Secretary-Treasurer

Meeting Report :

by Helene Hill

Annual Meeting - American Society for Photobiology

June 17-22, Washington DC

The ASP held its annual meeting in Washington, DC on June 17- 22, 1995 at the Hyatt Regency Capitol Hill Hotel. The weather was spectacular and we could sense the nation's heart beat as the days passed. Members of the press, legislators and others with a potential interest were invited to attend a pre-meeting workshop entitled **What is Photobiology?** organized by Frank Gasparro and held on Saturday, June 17. The session was well-attended in spite of weekend lure of the out-of-doors for Washington weekday shut-ins. Even veteran photobiologists had something to gain from this very stimulating session beamed at intelligent and educated laypersons. The workshop's success is reflected in the recent editorial in the *Journal of the American Medical Association* (August 9, 1995) entitled **New Light on Skin Cancer Mechanisms** by Charles Marwick. The article is summarized on our Web page which we invite all to visit (http://www/kumc.edu/ASP/pol_v01.htm).

Nik Kollias, well-known to the pigment cell world, organized a short course on **Photodermatology** along with Rox Anderson. This is a popular annual event which this year provided a critical update on the clinical status of photodynamic therapy in a number of skin conditions.

For us early risers (ugh) there was **Photobiology School** almost every morning at 8:00 AM. Topics covered included 'Carbenes and Nitrenes as Reagents for Photoaffinity Labeling Experiments' by Matthew Platz; 'Exclusion Studies: a Useful Technique for Assessing the Impact of Solar UV Radiation' by Donald Krizek; 'FDA Approval' by David Dolphin and 'The Possible Biological Effects of Electromagnetic Fields: A Review of Data and Concepts' by Jerry Williams.

Division meetings were held on the one morning without a school. The Society has subdivided itself into 5 sub-groups. These are 1.) Photochemistry, Photophysics and Phototechnology; 2.) Photosensory Biology; 3.) Photosynthesis and Photoconversion; 4.) Photomedicine; and 5.) Environmental Photobiology and UVR Effects. Each annual meeting is designed to have symposia, lectures, paper sessions, etc. that will be of interest to each division. Perspectives Lectures focus on each of the 5 divisions and are presented by eminent researchers in each field. Papers in our journal, **Photochemistry and Photobiology**, are grouped by Division. Pigment cell biologists who would like to join the ASP should have no trouble finding a suitable niche.

One of the most fascinating Symposia, entitled **The Effects of UV-B Light on Natural Ecosystems**, was organized by David Mitchell. The session dealt with such varied topics as photodamage in marine bacterioplankton, DNA damage in plants reared outdoors compared to indoors, the correlation of low photolyase with the decline of amphibian species and the genetic analysis of UVB-induced melanomas in Xiphophorine fish. Two interesting sessions were devoted to the **Biomedical Effects of Ozone Loss** and were organized by Thomas Coohill. Topics varied from measurement of UVB, immune suppression by UVB and assessment of sunscreens to consideration of the effect of increased UVB on phytoplankton. It is clear that there is much still to be learned in this important area.

Of particular interest to pigment cell researchers was the Symposium organized by Nik Kollias and Arthur Sober on **UV-Induced Cutaneous Malignant Melanoma**. Topics covered included epidemiology by Arthur Sober from whom we learned that about 2/3rds of melanomas worldwide are due to sunlight; hereditary melanoma by Ken Kraemer who demonstrated that lymphoblastoid cell lines from patients with familial malignant melanoma show abnormally high sensitivity to UVB mutagenesis; UV-induced melanomas in marsupials by Ron Ley who showed that the type of dietary fat can influence UV induction of melanoma; wavelength dependence of melanomas in fish by Dick Setlow who warned that conventional sunscreens by decreasing erythema with its action spectrum maximum in the UVB may actually lead to an increase in melanoma due to the disproportionate amount of UVA in sunlight and the enhanced sensitivity of melanomas to longer wave lengths. The

final talk was by Meenhard Herlyn who is well-known to the PASPCR and described a model for the study of UV transformation of human melanocytes.

Two ASP members were honored at the meeting. Jim Cleaver received the ASP Award and delivered a lecture on **Mending Human Genes**. Jim, as most already know, discovered the repair defect in xeroderma pigmentosum and has continued to do seminal work in this field ever since. The New Investigator Award went to Thomas Akmar whose award lecture was about the **Photoactive Mechanism of Rhodopsin**.

Of special interest to women and minorities was the Forum which met at noon on Monday, June 19. While all ASP members are invited, the Forum is a gathering where women and minorities can discuss their problems, share experiences and meet and get to know each other. This past year we have produced a register which we hope to circulate to interested parties such as potential employers, organizers of study sections, meetings, review groups, etc. We hope in this manner to get more women and minorities into leadership roles in the Society and in the outside world, as well. At our next annual meeting, we hope to sponsor an eminent female or minority speaker who will not only present good science but will also spend some time talking about the road she/he traveled to arrive where she/he is today. Many young women and minorities feel shy and lonely at national meetings. We hope next year to have a gathering place for people who don't know many others to meet to go to lunch or dinner together. There will, of course, be no restrictions on who participates (i.e. men and majorities are also welcome). This should be especially helpful to students and post-docs.

Next year, the Society will meet in Atlanta, GA on June 15 - 19, 1996. Information about the meeting can be found on our Web page or may be obtained by calling, writing, or faxing to the Secretariat: Dr. Sherwood M. Reichard, 1021 15th Street, Suite 9, Augusta, GA 30901. Tel: 706-722-7511; fax: 706-721-3048. Zalfa Abdel-Malek and I are organizing a Symposium on Melanin Photobiology that will be co-sponsored by the ASP and the PASPCR. It will focus on photoprotection versus photosensitization. If anyone would like to suggest relevant topics and/or speakers (self-nomination is allowed) please let one of us know. On that same subject, I am organizing a Symposium-in-Print to appear in **Photochemistry and Photobiology** some time next year. If anyone would be interested in submitting a manuscript to me, please either do so or let me know of your intent. I would like to have all of the manuscripts in by the end of the year.

Members in the News

Aaron Lerner was awarded the PASPCR Career Achievement Award for 1996; it was presented to him during the PASPCR Annual Meeting held in Kansas City.

Maher Haddad received a Young Investigator Award at the PASPCR Annual Meeting in Kansas City.

William Oetting received a Young Investigator Award at the PASPCR Annual Meeting in Kansas City.

Scott Wildenberg received a Young Investigator Award at the PASPCR Annual Meeting in Kansas City.

Positions - Wanted and Available :

Predoctoral Position - Opportunity available to do graduate studies towards a doctoral degree at the University of Cincinnati College of Medicine. Graduate program is through the Department of Cell Biology, Neurobiology, & Anatomy. Dissertation project would focus on molecular biology of the melanocyte physiology and pigmentary diseases. For information contact: Raymond E. Boissy, Ph.D., Department of Dermatology, University of Cincinnati College of Medicine, 231 Bethesda Avenue ML-592, Cincinnati, Ohio 45267-0592; (513)558-6242 [TEL]; (513)558-0198 [FAX]; boissyre@ucbeh.san.uc.edu [eMAIL].

Faculty Position - Massachusetts General Hospital, Harvard Medical School, Cutaneous Biology Research Center. The Cutaneous Biology Research Center (CBRC) seeks a molecular, cellular or developmental biologist to establish a program in fundamental research relevant to skin pigmentation. Areas of reseearch can include but are not limited to pigment synthesis and transfer in melanocytes, genetics of mouse coat color and development/migration of neural crest cells. Applicants must have a Ph.D. and/or M.D. degree and relevant postdoctoral experience. Only applicants with a strong research record and the potential to develop extramurally supported research programs will be considered. Individuals with a demonstrated ability to develop imaginative approaches to important biological questions are particularly encouraged to apply. Rank/salary/start-up funds and space are negotiable depending on experience and qualifications. The CBRC occupies 45,000 square feet of fully equipped laboratory space in a new multidisciplinary research facility. Interested individuals should send curriculum vitae, reprints, a statement of research and future directions, along with the names, addresses and telephone numbers of three references to: Dr. Paul F. Goetinck, Chair, Faculty Search Committee, Cutaneous Biology Research Center, Massachusetts General Hospital - East, Building 149, 13th Street, Charlestown, MA 02129

Director, Section of Basic Science Research - the Department of Dermatology and the Research Institute of the Cleveland Clinic Foundation are seeking applications for a full-time research scientist. Candidates should possess an M.D. and/or Ph.D. degree and have research experience in one of the following areas: wound healing, keratin/collagen biochemistry, or cancer immunology/molecular biology. The successful candidtate will have the ability to work as an independent investigator and be the focus for dermatological research in a dynamic, multi-disciplinary and supportive environment. Preference will be given to individuals who have demonstrated prior success in obtaining extramural support. Salary and title will be commensurate with training and experience. A University affiliation is available. Send C.V. to: Charles Camisa, M.D., Vice-Chair, Department of Dermatology, A61, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195-5032.

INTERPIG DataBase

by Vincent Hearing

The INTERPIG database is underway! Following is the current listing of supplies and suppliers that have been entered int the database. Please note that as of this time, only 4 PASPCR members have contributed entries (this represents only about 3% of our membership). Think of how useful and complete this list would be if everyone took the time to supply their own information. Please take a moment to fill out the database data entry form and send it back to Dr. Hearing (a copy of the entry form is inserted into this Newsletter, and it can be photocopied).

IFPCS DataBase Supplies and Suppliers Summary (current as of: February 13, 2008)

<u>Category</u>	<u># Entries</u>	<u>Society</u>	<u># contributors</u>
Animals :	35	ESPCR :	10
Biochemical/Chemical :	17	JSPCR :	0
Cell Culture :	7	PASPCR :	4
Dermatology/Clinical :	0		
Immunology :	11		
Molecular Biology :	0		
Other :	0		

Full Name: Dr. Dorothy Bennett (3)
Institution: St. George's Hospital Medical School
Department: Department of Anatomy
Building/Room: University of London
Street Address: Cranmer Terrace, Tooting
City: London
Postal Code: SW 17
Country: United Kingdom
Work Phone: 44-81-725-5202
Fax Number: 44-81-725-3326
Email Address:
ESPCR: X
Nonprofit: X

Full Name: Christopher John Cooksey (6)
Institution: University College London
Department: Department of Chemistry
Building/Room: Room 428
Street Address: 20 Gordon Street
City: London
Postal Code: WC1H 0AJ
Country: United Kingdom
Work Phone: 44-171-380-7777-4694
Fax Number: 44-171-380-7463
Email Address: ucca54c@ucl.ac.uk
ESPCR: X
Nonprofit: X

Full Name: Dr. Mary K. Cullen (1)
Institution: Washington University School of Medicine
Department: Dept of Cell Biology and Physiology
Building/Room: Box #8228
Street Address: 660 S. Euclid Street
City: St. Louis
State/Province: Missouri
Postal Code: 63110
Country: USA
Work Phone: 01-314-362-1082
Fax Number: 01-314-362-7463
Email Address: mkcullen@cellbio.wash.edu
PASPCR: X
Nonprofit: X

Full Name: Drs. Eric Donois & Jean-Etienne (1)
Surlève-Bazeille
Institution: Université Bordeaux I
Department: Dépt de Microscopie Electronique
Street Address: 351, Cours de la Libération
City: Talence
Postal Code: 33405 Talence Cedex
Country: France
Work Phone: 33-56-84-63-88
Fax Number: 33-56-84-66-70
Email Address:
ESPCR: X
Nonprofit: X

Full Name: Dr. Vincent J Hearing (5)
Institution: National Institutes of Health
Department: Laboratory of Cell Biology
Building/Room: Building 37 Room 1B25
Street Address: 9000 Rockville Pike
City: Bethesda
State/Province: MD

Postal Code: 20892
Country: USA
Work Phone: 01-301-496-1564
Fax Number: 01-301-402-8787
Email Address: hearingv@dc37a.nci.nih.gov
ESPCR: X
PASPCR: X
Nonprofit: X

Full Name: Prof. Kowichi Jimbow (7)
Institution: University of Alberta
Department: Department of Dermatology & Cutaneous Sciences
Building/Room: 260G Heritage Medical Research Center
City: Edmonton
State/Province: Alberta
Postal Code: T5K 0H2
Country: Canada
Work Phone: 01-403-492-2425
Fax Number: 01-403-492-7715
Email Address: kjimbow@gpu.srv.ualberta.ca
PASPCR: X
Nonprofit: X

Full Name: Dr. M. Lynn Lamoreux (35)
Institution: Texas A & M University
Department: Dept of Veterinary Pathobiology
City: College Station
State/Province: TX
Postal Code: 77843
Country: USA
Work Phone: 01-409-845-6084
Fax Number: 01-409-845-9972
Email Address: llamoreux@vetmed.tamu.edu
PASPCR: X
Nonprofit: X

Full Name: Dr. Anna Palumbo (1)
Institution: Stazione Zoologica
Street Address: Villa Comunale
City: Naples
Postal Code: 80121
Country: Italy
Work Phone: 39-81-583-3276
Fax Number: 39-81-764-1355
Email Address:
ESPCR: X
Nonprofit: X

Full Name: Prof. Dr. Martn G. Peter (1)
Institution: Universitaet Potsdam
Department: Department of Organische Chemie
Building/Room: Haus 9
Street Address: Am Neuen Palais 10
City: Potsdam
Postal Code: D-14469
Country: Germany
Work Phone: 49-331-977-1450
Fax Number: 49-331-977-1131
Email Address: peter@serv.chem.uni-potsdam.de
ESPCR: X
Nonprofit: X

Full Name: Dr. Ralf U. Peter (1)

Institution: University of Munich
Department: Department of Dermatology
Street Address: Frauenlobstrasse 9-11
City: Munich
State/Province: Bavaria
Postal Code: 80337
Country: Germany
Work Phone: 49-89-3168-3897
Fax Number: 49-89-5160-4527
Email Address:
ESPCR: X
Nonprofit: X

Full Name: Prof. Giuseppe Prota (5)
Institution: University of Naples
Department: Dept of Organic & Biological Chem
Street Address: Mezzocannone 16
City: Naples
Postal Code: 80134
Country: Italy
Work Phone: 39-81-704-1249
Fax Number: 39-81-552-1217
Email Address:
ESPCR: X
Nonprofit: X

Full Name: Prof. Patrick A. Riley (2)
Institution: UCL Medical School
Department: Department of Molecular Pathology
Building/Room: Windeyer Building
Street Address: Cleveland Street
City: London
Postal Code: W1P 6DB
Country: United Kingdom
Work Phone: 44-171-380-9323
Fax Number: 44-171-637-4436
Email Address: rebc900@ucl.ac.uk
ESPCR: X
Nonprofit: X

Full Name: Dr. Maria Anna Rosei (1)
Institution: University La Sapienza
Department: Department of Biochemical Sciences
Street Address: Piazza A. Moro, 5
City: Rome
Postal Code: 00185
Country: Italy
Work Phone: 39-6-4991-0923
Fax Number: 39-6-4440-062
Email Address:
ESPCR: X
Nonprofit: X

Full Name: Dr. Alain Taieb (2)
Institution: University of Bordeaux 2
Department: Department of Dermatology
Building/Room: 1B, Carreire Nord
Street Address: 146, Rue led Saignat
City: Bordeaux
Postal Code: 33076
Country: France
Work Phone: 33-56-79-56-22
Fax Number: 33-56-79-59-87
Email Address:
ESPCR: X
Nonprofit: X

Animals (35)

Item: C57BL/6J-c^{2j}/c^{2j} B/B
Description: albino black mice
Method: animals
Quantity: upon request
Reference:
Comment: must order in advance - \$25 service charge plus shipping costs
Source: Dr. M. Lynn Lamoreux

Item: C57BL/6J-c^{2j}/c^{2j} b/b
Description: albino brown mice
Method: animals
Quantity: upon request
Reference:
Comment: must order in advance - \$25 service charge plus shipping costs
Source: Dr. M. Lynn Lamoreux

Item: C57BL/6J-c^{ch}/c^{ch} B/B
Description: chinchilla black mice
Method: animals
Quantity: upon request
Reference:
Comment: must order in advance - \$25 service charge plus shipping costs
Source: Dr. M. Lynn Lamoreux

Item: C57BL/6J-c^{ch}/c^{ch} b/b
Description: chinchilla brown mice
Method: animals
Quantity: upon request
Reference:
Comment: must order in advance - \$25 service charge plus shipping costs
Source: Dr. M. Lynn Lamoreux

Item: C57BL/6J-c^p/c^p
Description: platinum mice
Method: animals
Quantity: upon request
Reference:
Comment: must order in advance - \$25 service charge plus shipping costs
Source: Dr. M. Lynn Lamoreux

Item: C57BL/6J-c^a/c^a
Description: acromelanin mice
Method: animals
Quantity: upon request
Reference:
Comment: must order in advance - \$25 service charge plus shipping costs
Source: Dr. M. Lynn Lamoreux

Item: C57BL/6J-c^h/c^h
Description: himalayan mice
Method: animals
Quantity: upon request
Reference:
Comment: must order in advance - \$25 service charge plus shipping costs
Source: Dr. M. Lynn Lamoreux

Item: C57BL/6J-c^{em}/c^{em}
Description: extreme dilution mottled mice
Method: animals
Quantity: upon request

Reference:
Comment: must order in advance - \$25 service charge plus shipping costs
Source: Dr. M. Lynn Lamoreux

Item: C57BL/6J-c^m/c^m
Description: mottled mice
Method: animals
Quantity: upon request
Reference:
Comment: must order in advance - \$25 service charge plus shipping costs
Source: Dr. M. Lynn Lamoreux

Item: c^{6H}/c^{ch}
Description: albino mice
Method: animals
Quantity: upon request
Reference:
Comment: must order in advance - \$25 service charge plus shipping costs
Source: Dr. M. Lynn Lamoreux

Item: c^{14CoS}/c^{ch}
Description: albino mice
Method: animals
Quantity: upon request
Reference:
Comment: must order in advance - \$25 service charge plus shipping costs
Source: Dr. M. Lynn Lamoreux

Item: C57BL/6J
Description: black mice
Method: animals
Quantity: upon request
Reference:
Comment: must order in advance - \$25 service charge plus shipping costs
Source: Dr. M. Lynn Lamoreux

Item: C57BL/6J-p^{un}/p^{un}
Description: pinkeyed unstable mice
Method: animals
Quantity: upon request
Reference:
Comment: must order in advance - \$25 service charge plus shipping costs
Source: Dr. M. Lynn Lamoreux

Item: C57BL/6J-slt/slt
Description: slaty mice
Method: animals
Quantity: upon request
Reference:
Comment: must order in advance - \$25 service charge plus shipping costs
Source: Dr. M. Lynn Lamoreux

Item: fd/fd
Description: faded mice
Method: animals
Quantity: upon request
Reference:
Comment: must order in advance - \$25 service charge plus shipping costs
Source: Dr. M. Lynn Lamoreux

Item: si/si

Description: silver mice
Method: animals
Quantity: upon request
Reference:
Comment: must order in advance - \$25 service charge plus shipping costs
Source: Dr. M. Lynn Lamoreux

Item: C57BL/6J-Mi^{wh}/mi
Description: microphthalmia mice
Method: animals
Quantity: upon request
Reference:
Comment: must order in advance - \$25 service charge plus shipping costs
Source: Dr. M. Lynn Lamoreux

Item: C57BL/6J-Mi^{wh}/mi^{sp}
Description: microphthalmia mice
Method: animals
Quantity: upon request
Reference:
Comment: must order in advance - \$25 service charge plus shipping costs
Source: Dr. M. Lynn Lamoreux

Item: mi^{rw}/mi^{vit}
Description: microphthalmia mice
Method: animals
Quantity: upon request
Reference:
Comment: must order in advance - \$25 service charge plus shipping costs
Source: Dr. M. Lynn Lamoreux

Item: mi^{ws}/mi^{ws}
Description: microphthalmia mice
Method: animals
Quantity: upon request
Reference:
Comment: must order in advance - \$25 service charge plus shipping costs
Source: Dr. M. Lynn Lamoreux

Item: Mi^{OR}/mi^{vit}
Description: microphthalmia mice
Method: animals
Quantity: upon request
Reference:
Comment: must order in advance - \$25 service charge plus shipping costs
Source: Dr. M. Lynn Lamoreux

Item: mi^{ce}/mi^{vit}
Description: microphthalmia mice
Method: animals
Quantity: upon request
Reference:
Comment: must order in advance - \$25 service charge plus shipping costs
Source: Dr. M. Lynn Lamoreux

Item: mi^{vit}/mi^{vit}
Description: microphthalmia mice
Method: animals
Quantity: upon request
Reference:
Comment: must order in advance - \$25 service charge plus shipping costs

Source: Dr. M. Lynn Lamoreux

Item:
Description: belted mice
Method: animals
Quantity: upon request
Reference:
Comment: must order in advance - \$25 service charge plus shipping costs
Source: Dr. M. Lynn Lamoreux

Item: C57BL/6J-W^{J2}/+
Description: Jay's dominant spotting mice
Method: animals
Quantity: upon request
Reference:
Comment: must order in advance - \$25 service charge plus shipping costs
Source: Dr. M. Lynn Lamoreux

Item: ls/ls
Description: lethal spotting mice
Method: animals
Quantity: upon request
Reference:
Comment: must order in advance - \$25 service charge plus shipping costs
Source: Dr. M. Lynn Lamoreux

Item: Ju/FcCtLm-c+c+ Rw/+
Description: Rump white mice
Method: animals
Quantity: upon request
Reference:
Comment: must order in advance - \$25 service charge plus shipping costs
Source: Dr. M. Lynn Lamoreux

Item: C57BL/6J-Ay/a
Description: lethal yellow mice
Method: animals
Quantity: upon request
Reference:
Comment: must order in advance - \$25 service charge plus shipping costs
Source: Dr. M. Lynn Lamoreux

Item: C57BL/6J-Ay/a b/b
Description: lethal yellow, brown mice
Method: animals
Quantity: upon request
Reference:
Comment: must order in advance - \$25 service charge plus shipping costs
Source: Dr. M. Lynn Lamoreux

Item: C57BL/6J-Ay/a mg/mg
Description: lethal yellow, mahogany mice
Method: animals
Quantity: upon request
Reference:
Comment: must order in advance - \$25 service charge plus shipping costs
Source: Dr. M. Lynn Lamoreux

Item: JU/FcCtLm Ay/a
Description: lethal yellow mice
Method: animals
Quantity: upon request

Reference:
Comment: must order in advance - \$25 service charge plus shipping costs
Source: Dr. M. Lynn Lamoreux

Item: C57BL/6J-a^m/a^m
Description: nonagouti mottled mice
Method: animals
Quantity: upon request
Reference:
Comment: must order in advance - \$25 service charge plus shipping costs
Source: Dr. M. Lynn Lamoreux

Item: JU/FcCTLM-a^m/a^m
Description: nonagouti mottled mice
Method: animals
Quantity: upon request
Reference:
Comment: must order in advance - \$25 service charge plus shipping costs
Source: Dr. M. Lynn Lamoreux

Item: C57BL/6J-e/e
Description: recessive yellow mice
Method: animals
Quantity: upon request
Reference:
Comment: must order in advance - \$25 service charge plus shipping costs
Source: Dr. M. Lynn Lamoreux

Item: C57BL/6J-E^{so}/E^{so}
Description: sombre mice
Method: animals
Quantity: upon request
Reference:
Comment: must order in advance - \$25 service charge plus shipping costs
Source: Dr. M. Lynn Lamoreux

Biochemicals / Chemicals (17)

Item: catecholamines
Description: labeled compounds, stable isotopes
Method: chemistry
Quantity: upon request
Reference: Liebigs Annalen der chemie, 563-567, 1994
Comment:
Source: Prof. Dr. Martn G. Peter

Item: Quantimel Program
Description: stereological image analysis for quantitation of melanization
Method: electron microscopy
Quantity:
Reference:
Comment: tool for the estimation of the melanin and melanosome content, especially for cultured cells
Source: Drs. Eric Donois & Jean-Etienne Surlève-Bazeille

Item: opiomelanins
Description: soluble melanins from opioid peptides
Method: biochemistry
Quantity:

Reference: Biochim Biophys Acta 1199:123-129, 1994

Comment:
Source: Dr. Maria Anna Rosei

Item: PTCA
Description: standardized solution for HPLC
Method: chemistry
Quantity: 5-10 µg/ml
Reference:
Comment: prepared by degradation of DHICA with alkaline H₂O₂
Source: Prof. Giuseppe Prota

Item: DOPA melanin
Description: black powder, equilibrated on saturated CaCl₂
Method: chemistry
Quantity: 10-50 mg
Reference: Gazz Chim Ital 123:241-242, 1993
Comment: tyrosinase catalyzed oxidation of DOPA / pH 7.0, 25 C, 2.5 hr
Source: Prof. Giuseppe Prota

Item: DHICA melanin(s)
Description: black powder
Method: chemistry
Quantity: 5-10 mg
Reference:
Comment: prepared by enzymic oxidation of DHICA
Source: Prof. Giuseppe Prota

Item: DHI melanin(s)
Description: black powder
Method: chemistry
Quantity: 5-10 mg
Reference:
Comment: prepared by enzymic oxidation of DHI
Source: Prof. Giuseppe Prota

Item: 5-S-cysteinylDOPA
Description: white crystalline powder
Method: chemistry
Quantity: 5 mg
Reference: Synth Commun 16:967-971, 1986
Comment: prepared by chemical oxidation of DOPA
Source: Prof. Giuseppe Prota

Item: sepiomelanin
Description: black powder hygroscopic
Method: chemistry
Quantity: 50 mg
Reference:
Comment: prepared by centrifugation of the fresh ink of Sepia, dried over silica gel and equilibrated in CaCl₂
Source: Dr. Anna Palumbo

Item: KUI/1
Description: 4-methoxyphenyl-1alpha(D)-mannopyranoside (KUI)
Method: biochemistry
Quantity: 10 mg
Reference: Melanoma Res 1:273-287, 1991
Comment: tyrosinase analogue substrate XXII
Source: Prof. Patrick A. Riley

Item: KUI/2
Description: 4-methoxyphenyl-1 β (D)-glucopyranoside (KUI)
Method: biochemistry
Quantity: 10 mg
Reference: Melanoma Res 1:273-287, 1991
Comment: tyrosinase analogue substrate XXIII
Source: Prof. Patrick A. Riley

Item: 4-propoxyphenol
Description: substituted phenol substrate for tyrosinase
Method: biochemistry
Quantity: 10 mg
Reference: Melanoma Res 1:273-287, 1991
Comment: tyrosinase analogue
Source: Christopher John Cooksey

Item: 4-(2-hydroxyethylthio)phenol
Description: substituted phenol substrate for tyrosinase
Method: biochemistry
Quantity: 10 mg
Reference: Melanoma Res 1:273-287, 1991
Comment: tyrosinase analogue
Source: Christopher John Cooksey

Item: 4-(2-hydroxyethoxy)phenol
Description: substituted phenol substrate for tyrosinase
Method: biochemistry
Quantity: 10 mg
Reference: Melanoma Res 1:273-287, 1991
Comment: tyrosinase analogue
Source: Christopher John Cooksey

Item: 4-isobutoxyphenol
Description: substituted phenol substrate for tyrosinase
Method: biochemistry
Quantity: 10 mg
Reference: Melanoma Res 1:273-287, 1991
Comment: tyrosinase analogue
Source: Christopher John Cooksey

Item: 4(2-bromoethoxy)phenol
Description: substituted phenol substrate for tyrosinase
Method: biochemistry
Quantity: 10 mg
Reference: Melanoma Res 1:273-287, 1991
Comment: tyrosinase analogue
Source: Christopher John Cooksey

Item: 4-(2thioethylthio)phenol
Description: substituted phenol substrate for tyrosinase
Method: biochemistry
Quantity: 10 mg
Reference: Melanoma Res 1:273-287, 1991
Comment: tyrosinase analogue
Source: Christopher John Cooksey

Item: N-acetyl-4-S-cysteaminyphenol
Description: substituted phenol substrate for tyrosinase
Method: biochemistry
Quantity: 5 mg
Reference: Cancer Res 50:3743-3747, 1990

Comment: tyrosinase substrate
Source: Prof. Kowichi Jimbow

Cell Culture (7)

Item: melan-a cells
Description: black C57BL/6 murine melanocyte line
Method: cell culture
Quantity: 1 ml
Reference: Int. J. Cancer 39:414-418, 1987
Comment: immortalized from a C57Bl/6 mouse
Source: Dr. Dorothy Bennett

Item: melan-b cells
Description: brown (b/b) murine melanocyte line
Method: cell culture
Quantity: 1 ml
Reference: Development 105:379-385, 1989
Comment: immortalized from a b/b mouse of Falconer's Q-strain
Source: Dr. Dorothy Bennett

Item: melan-c cells
Description: albino (c/c) murine melanocyte line
Method: cell culture
Quantity: 1 ml
Reference: Development 105:379-385, 1989
Comment: immortalized from partially-outbred LAC-MF1 Swiss mice
Source: Dr. Dorothy Bennett

Item: reconstructed epidermis
Description: with melanocytes
Method: cell culture
Quantity:
Reference: Pigment Cell Res (in press), 1995
Comment: allows pharmacological and pathophysiological studies
Source: Dr. Alain Taieb

Item: melanocyte culture
Description: without phorbol esters and cAMP agonists
Method: cell culture
Quantity:
Reference: Arch Dermatol Res 285:385-392, 1993
Comment: allows physiological assays on melanocytes ex vivo
Source: Dr. Alain Taieb

Item: Irradiated melanoma cells
Description: human cell lines irradiated (240 kV) X-ray
Method: cell culture
Quantity: 10⁸ cells
Reference:
Comment: a system to study increased tyrosine kinase expression
Source: Dr. Ralf U. Peter

Item: Neonatal human melanocytes
Description: black, caucasian or mixed - primary culture
Method: tissue culture
Quantity: 2x10⁶ cells
Reference: J. Invest. Dermatol. 97:395-404, 1991

Comment: will supply only investigators without access to human skin, or who have lost their primary culture lines
Source: Dr. Mary K. Cullen

Dermatology / Clinical (0)

Immunology (11)

Item: α -PEP1
Description: TRP1 antibody
Method: immunology
Quantity: 1 ml
Reference: J Biol Chem 264:3397-3403, 1989
Comment: recognizes mouse, but not human
Source: Dr. Vincent J Hearing

Item: α -PEP7
Description: tyrosinase antibody
Method: immunology
Quantity: 1 ml
Reference: J Biol Chem 266:1147-1156, 1991
Comment: recognizes mouse and human (weakly)
Source: Dr. Vincent J Hearing

Item: α -PEP8
Description: TRP2 antibody
Method: immunology
Quantity: 1 ml
Reference: EMBO J 11:519-526, 1992
Comment: recognizes mouse and human
Source: Dr. Vincent J Hearing

Item: α -PEP13
Description: silver antibody
Method: immunology
Quantity: 1 ml
Reference: J Biol Chem 269:29198-29205, 1994
Comment: recognizes mouse and human
Source: Dr. Vincent J Hearing

Item: α -PEP5
Description: tyrosinase antibody
Method: immunology
Quantity: 1 ml
Reference: J Biol Chem 266:1147-1156, 1991
Comment: recognizes mouse and human (strongly) if denatured
Source: Dr. Vincent J Hearing

Item: HMSA-1
Description: MoAb to human melanosome specific antigen - 1, mouse IgG1 k
Method: immunology
Quantity: 0.5 ml
Reference: J Invest Dermatol 100:259S-268S, 1993
Comment: these antibodies can also be used for routine paraffin sections
Source: Prof. Kowichi Jimbow

Item: HMSA-2
Description: MoAb to human melanosome specific antigen - 2, mouse IgG1 k
Method: immunology
Quantity: 0.5 ml
Reference: J Invest Dermatol 100:259S-268S, 1993

Comment: these antibodies can also be used for routine paraffin sections
Source: Prof. Kowichi Jimbow

Item: HMSA-3
Description: MoAb to human melanosome specific antigen - 3, mouse IgM k
Method: immunology
Quantity: 0.5 ml
Reference: J Invest Dermatol 100:259S-268S, 1993
Comment: these antibodies can also be used for routine paraffin sections
Source: Prof. Kowichi Jimbow

Item: HMSA-4
Description: MoAb to human melanosome specific antigen - 4, mouse IgM k
Method: immunology
Quantity: 0.5 ml
Reference: J Invest Dermatol 100:259S-268S, 1993
Comment: these antibodies can also be used for routine paraffin sections
Source: Prof. Kowichi Jimbow

Item: HMSA-5
Description: MoAb to human melanosome specific antigen - 5, mouse IgG1 k
Method: immunology
Quantity: 0.5 ml
Reference: J Invest Dermatol 100:259S-268S, 1993
Comment: these antibodies can also be used for routine paraffin sections
Source: Prof. Kowichi Jimbow

Item: HMSA-7
Description: MoAb to human melanosome specific antigen - 7, mouse IgG1, k
Method: immunology
Quantity: 0.5 ml
Reference: Melanoma Res 3:331-335, 1993
Comment: these antibodies can also be used for routine paraffin sections
Source: Prof. Kowichi Jimbow

Molecular Biology (0)

Other (0)

Bibliography :

The Bibliography published in this issue covers the period February, 1995 through April, 1995. If you notice a paper that was not detected by this search that should be included, please send it to us and we will include it in the next issue. We have attempted to highlight any publications which include a member of the PASPCR with a star.

MELANINS, MELANOGENS & MELANOGENESIS

- Alena F, Dixon W, Thomas P, Jimbow K: Glutathione plays a key role in the depigmenting and melanocytotoxic action of N-acetyl-4-S-cysteaminyphenol in black and yellow hair follicles. *J Invest Dermatol* 104:792-797 (1995).
- Ando H, Itoh A, Mishima Y, Ichihashi M: Correlation between the number of melanosomes, tyrosinase mRNA levels, and tyrosinase activity in cultured murine melanoma cells in response to various melanogenesis regulatory agents. *J Cell Physiol* 163:608-614 (1995).
- Archambault M, Yaar M, Gilchrist BA: Keratinocytes and fibroblasts in a human skin equivalent model enhance melanocyte survival and melanin synthesis after ultraviolet irradiation. *J Invest Dermatol* 104:859-867 (1995).
- Blasi E, Barluzzi R, Mazzolla R, Tancini B, Saleppico S, Puliti M, Pitzurra L, Bistoni F: Role of nitric oxide and melanogenesis in the accomplishment of anticryptococcal activity by the BV-2 microglial cell line. *J Neuroimmunol* 58:111-116 (1995).
- Bluetpajot MT, Presse F, Voko Z, Hoeger C, Mounier F, Epelbaum J, Nahon JL: Neuropeptide-E-I antagonizes the action of melanin-concentrating hormone on stress-induced release of adrenocorticotropin in the rat. *J Neuroendocrinol* 7:297-303 (1995).
- Bora NS, Kim MC, Kabeer NH, Simpson SC, Tandhasetti MT, Cirrito TP, Kaplan AD, Kaplan HJ: Experimental autoimmune anterior uveitis - Induction with melanin-associated antigen from the iris and ciliary body. *Invest Ophthalmol Visual Sci* 36:1056-1066 (1995).
- Caesartonthat TC, Kloeke FV, Geesey GG, Henson JM: Melanin production by a filamentous soil fungus in response to copper and localization of copper sulfide by sulfide-silver staining. *Appl Environ Microbiol* 61:1968-1975 (1995).
- Clarke CE: Does levodopa therapy delay death in Parkinson's disease? A review of the evidence. *Movement Disord* 10:250-256 (1995).
- Depotter P, Shields CL, Shields JA, Flanders AE: Does the melanin content of uveal malignant melanomas correlate with their magnetic resonance imaging appearance? In reply. *Arch Ophthalmol* 113:556(1995).
- Duttlinger R, Manova K, Berrozpe G, Chu TY, Deleon V, Timokhina I, Chaganti RSK, Zelenetz AD, Bachvarova RF, Besmer P: The W-sh and Ph mutations affect the c-kit expression profile: C-kit misexpression in embryogenesis impairs melanogenesis in W-sh and Ph mutant mice. *Proc Natl Acad Sci USA* 92:3754-3758 (1995).
- Farooqui JZ, Robb E, Boyce ST, Warden GD, Nordlund JJ: Isolation of a unique melanogenic inhibitor from human skin xenografts: Initial *in vitro* and *in vivo* characterization. *J Invest Dermatol* 104:739-743 (1995).
- Ferris J, Bloom P: Does the melanin content of uveal malignant melanomas correlate with their magnetic resonance imaging appearance? *Arch Ophthalmol* 113:555-556 (1995).
- Foss AJE, Alexander RA, Jefferies LW, Lightman S: Immunohistochemical techniques: The effect of melanin bleaching. *Brit J Biomed Sci* 52:22-25 (1995).
- Hiruma K, Carter MS, Riddiford LM: Characterization of the dopa decarboxylase gene of *Manduca sexta* and its suppression by 20-hydroxyecdysone. *Dev Biol* 169:195-209 (1995).
- Hu DN, McCormick SA, Orlov SJ, Rosembat S, Lin AY, Wo K: Melanogenesis by human uveal melanocytes *in vitro*. *Invest Ophthalmol Visual Sci* 36:931-938 (1995).
- Kageura H, Eguchi G, Yamana K: The origin and development of retinal pigment cells and melanophores analyzed by *Xenopus* black-white chimeras. *Dev Growth Differ* 37:157-166 (1995).
- Kameyama K, Sakai C, Kuge S, Nishiyama S, Tomita Y, Ito S, Wakamatsu K, Hearing VJ: The expression of tyrosinase, tyrosinase-related proteins 1 and 2 (TRP1 and TRP2), the silver protein, and a melanogenic inhibitor in human melanoma cells of differing melanogenic activities. *Pigm Cell Res* 8:97-104 (1995).
- Kobayashi T, Vieira WD, Potterf B, Sakai C, Imokawa G, Hearing VJ: Modulation of melanogenic protein expression during the switch from eu- to pheomelanogenesis. *J Cell Sci* 108:2301-2309 (1995).
- Korytowski W, Sarna T, Zareba M: Antioxidant action of neuromelanin: The mechanism of inhibitory effect on lipid peroxidation. *Arch Biochem Biophys* 319:142-148 (1995).
- Kotob SI, Coon SL, Quintero EJ, Weiner RM: Homogentisic acid is the primary precursor of melanin synthesis in *Vibrio cholerae*, a *Hyphomonas* strain, and *Shewanella colwelliana*. *Appl Environ Microbiol* 61:1620-1622 (1995).
- Kuwabara H, Cumming P, Yasuhara Y, Leger GC, Guttman M, Diksic M, Evans AC, Gjedde A: Regional striatal DOPA transport and decarboxylase activity in Parkinson's disease. *J Nucl Med* 36:1226-1231 (1995).
- Martinez-Liarte JH, Solano F, Lozano JA: Effect of penicillin-streptomycin and other antibiotics on melanogenic parameters in cultured B16/F10 melanoma cells. *Pigm Cell Res* 8:83-88 (1995).

- Mimaki Y, Kameyama A, Sashida Y, Miyata Y, Fujii A: A novel hexahydrodibenzofuran derivative with potent inhibitory activity on melanin biosynthesis of cultured B-16 melanoma cells from *Lindera umbellata* bark. *Chem Pharm Bull Tokyo* 43:893-895 (1995).
- Misu Y, Ueda H, Goshima Y: Neurotransmitter-like actions of L-DOPA. *Advances in Pharmacology*, Vol 32:427-459 (1995).
- Napolitano A, Crescenzi O, Pezzella A, Prota G: Generation of the neurotoxin 6-hydroxydopamine by peroxidase H₂O₂ oxidation of dopamine. *J Med Chem* 38:917-922 (1995).
- Napolitano A, Pezzella A, Vincenzi MR, Prota G: Oxidative degradation of melanins to pyrrole acids: A model study. *Tetrahedron* 51:5913-5920 (1995).
- Opackajuffry J, Brooks DJ: L-dihydroxyphenylalanine and its decarboxylase: New ideas on their neuroregulatory roles. *Movement Disord* 10:241-249 (1995).
- Pierce JA, Rast DM: A comparison of native and synthetic mushroom melanins by Fourier-transform infrared spectroscopy. *Phytochemistry* 39:49-55 (1995).
- Rajadhyaksha M, Grossman M, Esterowitz D, Webb RH: *In vivo* confocal scanning laser microscopy of human skin: Melanin provides strong contrast. *J Invest Dermatol* 104:946-952 (1995).
- Romanenko LA, Mikhailov VV, Lysenko AM, Stepanenko VI: A new species of melanin-producing bacteria of the genus *Alteromonas*. *Microbiology-Engl Tr* 64:60-62 (1995).
- ☞ Schmitz S, Thomas PD, Allen TM, Poznansky MJ, Jimbow K: Dual role of melanins and melanin precursors as photoprotective and phototoxic agents: Inhibition of ultraviolet radiation-induced lipid peroxidation. *Photochem Photobiol* 61:650-655 (1995).
- Smit NPM, Westerhof W, Smit W, Nanninga B, Pavel S: Some aspects of melanin formation of melanocytes cultured on collagen-coated microcarrier beads. *Pigm Cell Res* 8:89-96 (1995).
- Soaresdasilva P: Nature and kinetic characteristics of L-DOPA uptake in rat renal proximal tubules. *Amino Acids* 8:265-270 (1995).
- Stano J, Nemeč P, Weisssova K, Kovacs P, Kakoniova D, Liskova D: Decarboxylation of L-tyrosine and L-dopa by immobilized cells of *Papaver somniferum*. *Phytochemistry* 38:859-860 (1995).
- Stromskaya TP, Filippova NA, Rybalkina EY, Egudina SV, Shtil AA, Eliseenkova AV, Stavrovskaya AA: Alterations of melanin synthesis in human melanoma cells selected *in vitro* for multidrug resistance. *Exp Toxicol Pathol* 47:157-166 (1995).
- Takahashi K, Suzuki H, Totsune K, Murakami O, Satoh F, Sone M, Sasano H, Mouri T, Shibahara S: Melanin-concentrating hormone in human and rat. *Neuroendocrinology* 61:493-498 (1995).
- Varela JM, Stempels NA, Vandenberghe DA, Tassignon MJ: Isoenzymic patterns of tyrosinase in the rabbit choroid and retina/retinal pigment epithelium. *Exp Eye Res* 60:621-629 (1995).
- Watanabe S, Saito T: Circular dichroism and ultraviolet studies of the cupric(II)- and nickel(II)-L-3,4-dihydroxyphenylalanine complex. *J Inorg Biochem* 58:147-155 (1995).
- ☞ Wilczek A, Mishima Y: Inhibitory effects of melanin monomers, dihydroxyindole-2-carboxylic acid (DHICA) and dihydroxyindole (DHI) on mammalian tyrosinase, with a special reference to the role of DHICA/DHI ratio in melanogenesis. *Pigm Cell Res* 8:105-112 (1995).
- Zareba M, Bober A, Korytowski W, Zecca L, Sarna T: The effect of a synthetic neuromelanin on yield of free hydroxyl radicals generated in model systems. *Bba-Mol Basis Dis* 1271:343-348 (1995).
- Zhao SL, Thornquist SC, Barnstable CJ: *In vitro* transdifferentiation of embryonic rat retinal pigment epithelium to neural retina. *Brain Res* 677:300-310 (1995).

MELANOCYTES & KERATINOCYTES

- Abadir MC, Marghoob AA, Slade J, Salopek TG, Yadav S, Kopf AW: Case-control study of melanocytic nevi on the buttocks in atypical mole syndrome: Role of solar radiation in the pathogenesis of atypical moles. *J Am Acad Dermatol* 33:31-36 (1995).
- Aloi F, Solaroli C, Pippione M: Involution of melanocytic nevi by halo eczema (Meyerson's nevi). *European J Dermatology* 5:313-315 (1995).
- ☞ Austin LM, Boissy RE: Mammalian tyrosinase-related protein-1 is recognized by autoantibodies from vitiliginous Smyth chickens: An avian model for human vitiligo. *Am J Pathol* 146:1529-1541 (1995).
- Bakker ABH, Schreurs MWJ, Tafazzul G, Deboer AJ, Kawakami Y, Adema GJ, Figdor CG: Identification of a novel peptide derived from the melanocyte-specific gp100 antigen as the dominant epitope recognized by an HLA-A2.1-restricted anti-melanoma CTL line. *Int J Cancer* 62:97-102 (1995).
- Battayani Z, Grob JJ, Xerri L, Noe C, Zarour H, Houvaenaghel G, Delpero JR, Birmbaum D, Hassoun J, Bonerandi JJ: Polymerase chain reaction detection of circulating melanocytes as a prognostic marker in patients with melanoma. *Arch Dermatol* 131:443-447 (1995).
- Cable J, Jackson IJ, Steel KP: Mutations at the W locus affect survival of neural crest-derived melanocytes in the mouse. *Mech Develop* 50:139-150 (1995).
- Carli P, Biggeri A, Giannotti B: Malignant melanoma in Italy: Risks associated with common and clinically atypical melanocytic nevi. *J Am Acad Dermatol* 32:734-739 (1995).
- Dupin E, Ledouarin NM: Retinoic acid promotes the differentiation of adrenergic cells and melanocytes in quail neural crest cultures. *Dev Biol* 168:529-548 (1995).
- ☞ Durham-Pierre DG, Walters CS, Halder RM, Pham HN, Vanderpool EA: Natural killer cell and lymphokine-activated killer cell activity against melanocytes in vitiligo. *J Am Acad Dermatol* 33:26-30 (1995).

- ☞ Hann SK, Im S, Pong HW, Park YK: Treatment of stable vitiligo with autologous epidermal grafting and PUVA. *J Am Acad Dermatol* 32:943-948 (1995).
- ☞ Hou L, Kwon BS: Turtle lung cells produce a melanization-stimulating activity that promotes melanocytic differentiation of avian neural crest cells. *Pigm Cell Res* 8:113-119 (1995).
- Kageshita T, Yoshii A, Kimura T, Maruo K, Ono T, Himeno M, Nishimura Y: Biochemical and immunohistochemical analysis of cathepsins B, H, L and D in human melanocytic tumours. *Arch Dermatol Res* 287:266-272 (1995).
- Kazianis S, Borowsky R: Stable association of a pigmentation allele with an oncogene: Nonhybrid melanomas in *Xiphophorus variatus*. *J Hered* 86:199-203 (1995).
- Krasagakis K, Garbe C, Eberle J, Orfanos CE: Tumour necrosis factors and several interleukins inhibit the growth and modulate the antigen expression of normal human melanocytes *in vitro*. *Arch Dermatol Res* 287:259-265 (1995).
- Kubota R, Wang YM, Minoshima S, Kudoh J, Mashima Y, Oguchi Y, Shimizu N: Mapping of the human gene for a melanocyte protein Pmel 17 (D12S53E) to chromosome 12q13-q14. *Genomics* 26:430-431 (1995).
- Lecoin L, Lahav R, Martin FH, Teillet MA, Ledouarin NM: Steel and c-kit in the development of avian melanocytes: A study of normally pigmented birds and of the hyperpigmented mutant silky fowl. *Develop Dynam* 203:106-118 (1995).
- Masuda M, Yamazaki K, Kanzaki J, Hosoda Y: Ultrastructural evidence of cell communication between epithelial dark cells and melanocytes in vestibular organs of the human inner ear. *Anat Rec* 242:267-277 (1995).
- Masuda M, Yamazaki K, Matsunaga T, Kanzaki J, Hosoda Y: Melanocytes in the dark cell area of human vestibular organs. *Acta Oto-Laryngol* 152:157 (1995).
- Nataf V, Mercier P, Denechaud S, Guillemot JC, Capdevielle J, Lapointe F, Ledouarin NM: Melanoblast/melanocyte early marker (MelEM) is a glutathione S-transferase subunit. *Exp Cell Res* 218:394-400 (1995).
- Natali PG, Nicotra MR, Difilippo F, Bigotti A: Expression of fibronectin, fibronectin isoforms and integrin receptors in melanocytic lesions. *Br J Cancer* 71:1243-1247 (1995).
- Nogales FF, Luna MA, Vergara E, Ovalle F, Lopezcantarero M: Small-cell epidermoid carcinoma with melanocyte colonization arising in a mature ovarian cystic teratoma. *Arch Pathol Lab Med* 119:551-554 (1995).
- Oconnor TJ: Mechanism of c-SRC activation in human melanocytes: Elevated level of protein tyrosine phosphatase activity directed against the carboxy-terminal regulatory tyrosine. *Cell Growth Differ* 6:484(1995).
- Olsson MJ, Juhlin L: Transplantation of melanocytes in vitiligo. *Br J Dermatol* 132:587-591 (1995).
- Ortega VV, Diaz FM, Romero CC, Pacheco GO, Jordana MC, Rubiales FC: Abnormal melanosomes: Ultrastructural markers of melanocytic atypia. *Ultrastruct Pathol* 19:119-128 (1995).
- Peters TA, Kuijpers W, Tonnaer ELGM, Vanmuijen GNP, Jap PHK: Distribution and features of melanocytes during inner ear development in pigmented and albino rats. *Hear Res* 85:169-180 (1995).
- Powell MB, Hyman P, Bell OD, Balmain A, Brown K, Alberts D, Bowden GT: Hyperpigmentation and melanocytic hyperplasia in transgenic mice expressing the human T24 Ha-ras gene regulated by a mouse tyrosinase promoter. *Mol Carcinogen* 12:82-90 (1995).
- Reed JA, Loganzo F, Shea CR, Walker GJ, Flores JF, Glendening JM, Bogdany JK, Shiel MJ, Haluska FG, Fountain JW, Albino AP: Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression. *Cancer Res* 55:2713-2718 (1995).
- Reid K, Nishikawa SI, Bartlett PF, Murphy M: Steel factor directs melanocyte development *in vitro* through selective regulation of the number of c-kit(+) progenitors. *Dev Biol* 169:568-579 (1995).
- Rivers JK, MacLennan R, Kelly JW, Lewis AE, Tate BJ, Harrison S, McCarthy WH: The Eastern Australian childhood nevus study: Prevalence of atypical nevi, congenital nevus-like nevi, and other pigmented lesions. *J Am Acad Dermatol* 32:957-963 (1995).
- Schadendorf D, Kohlmus C, Gawlik C, Suter L, Czarnetzki BM: Mast cells in melanocytic tumours. *Arch Dermatol Res* 287:452-456 (1995).
- ☞ Spritz RA, Hearing VJ: Genetic disorders of pigmentation. *Advances in Human Genetics*, 22:1-45 (1994).
- Sviderskaya EV, Wakeling WF, Bennett DC: A cloned, immortal line of murine melanoblasts inducible to differentiate to melanocytes. *Development* 121:1547-1557 (1995).
- ☞ Swope VB, Medrano EE, Smalara D, Abdel-Malek ZA: Long-term proliferation of human melanocytes is supported by the physiologic mitogens α -melanotropin, endothelin-1, and basic fibroblast growth factor. *Exp Cell Res* 217:453-459 (1995).
- Tan JCS, Phang VPE: Inheritance of body pigmentation pattern in *Brachydanio rerio*. *J Hered* 86:231-232 (1995).
- Tronnier M, Kammerer R, Wolff HH: Proliferative activity of keratinocytes correlates with that of melanocytes in naevi and melanomas. *Arch Dermatol Res* 287:509-511 (1995).
- Tronnier M, Smolle J, Wolff HH: Ultraviolet irradiation induces acute changes in melanocytic nevi. *J Invest Dermatol* 104:475-478 (1995).
- ☞ Vijayasaradhi S, Houghton AN: Melanoma and melanocytes: Pigmentation, tumor progression, and the immune response to cancer. *Advances in Pharmacology*, Vol 32:343-374 (1995).
- ☞ Yamanishi DT, Meyskens FL: Alterations in gene expression and signal transductions in human melanocytes and melanoma cells. *Crit Rev Oncogenesis* 5:429-450 (1994).

- Zepter K, Haffner AC, Trefzer U, Elmetts CA: Reduced growth factor requirements and accelerated cell-cycle kinetics in adult human melanocytes transformed with SV40 large T antigen. *J Invest Dermatol* 104:755-762 (1995).
- Zvulunov A, Esterly NB: Neurocutaneous syndromes associated with pigmentary skin lesions. *J Am Acad Dermatol* 32:915-935 (1995).

MELANOMA & METASTASIS

- Akslen LA: Seasonal variation in melanoma progress. *J Nat Cancer Inst* 87:1025-1026 (1995).
- Alizadeh H, Ma D, Berman M, Bellingham D, Comerford SA, Gething MJH, Sambrook JF, Niederkorn JY: Tissue-type plasminogen activator-induced invasion and metastasis of murine melanomas. *Curr Eye Res* 14:449-458 (1995).
- Atzpodien J, Hanninen EL, Kirchner H, Franzke A, Korfer AK, Volkenandt M, Duensing S, Schomburg A, Chaitchik S, Poliwoda H: Chemoimmunotherapy of advanced malignant melanoma: Sequential administration of subcutaneous interleukin-2 and interferon- α after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen. *Eur J Cancer* 31A:876-881 (1995).
- Autier P, Dore JF, Schiffers E, Cesarini JP, Bollaerts A, Koelmel KF, Gefeller O, Liabeuf A, Lejeune F, Lienard D, Joarlette M, Chemaly P, Kleeberg UR: Melanoma and use of sunscreens: An EORTC case-control study in Germany, Belgium and France. *Int J Cancer* 61:749-755 (1995).
- Auzenne E, Feig B, Ross MI, Tomasovic SP, Klostergaard J: Tetramodality treatment of human melanoma *in vitro*. *Melanoma Res* 5:49-57 (1995).
- Baba H, Urano T, Okada K, Furukawa K, Nakayama E, Tanaka H, Iwasaki K, Shiku H: Two isotypes of murine nm23/nucleoside diphosphate kinase, nm23-M1 and nm23-M2, are involved in metastatic suppression of a murine melanoma line. *Cancer Res* 55:1977-1981 (1995).
- Bauer M, Reaman GH, Hank JA, Cairo MS, Anderson P, Blazar BR, Friedrich S, Sondel PM: A phase II trial of human recombinant interleukin-2 administered as a 4-day continuous infusion for children with refractory neuroblastoma, non-Hodgkin's lymphoma, sarcoma, renal cell carcinoma, and malignant melanoma: A children's cancer group study. *Cancer* 75:2959-2965 (1995).
- Belkhou R, Abbe JC, Pham P, Jasner N, Sahel J, Dreyfus H, Moutaouakkil M, Massarelli R: Uptake and metabolism of boronophenylalanine in human uveal melanoma cells in culture - Relevance to boron neutron capture therapy of cancer cells. *Amino Acids* 8:217-229 (1995).
- Berwick M, Chen YT: Reliability of reported sunburn history in a case-control study of cutaneous malignant melanoma. *Am J Epidemiol* 141:1033-1037 (1995).
- Beviglia L, Stewart GJ, Niewiarowski S: Effect of four disintegrins on the adhesive and metastatic properties of B16F10 melanoma cells in a murine model. *Oncol Res* 7:7-20 (1995).
- Bitan M, Mohsen M, Levi E, Wygoda MR, Miao HQ, Lider O, Svahn CM, Ekre HP, Ishaimichaeli R, Barshavit R, Vlodavsky I, Peretz T: Structural requirements for inhibition of melanoma lung colonization by heparanase inhibiting species of heparin. *Isr J Med Sci* 31:106-118 (1995).
- Bleehen NM, Newlands ES, Lee SM, Thatcher N, Selby P, Calvert AH, Rustin GJS, Brampton M, Stevens MFG: Cancer research campaign phase II trial of temozolomide in metastatic melanoma. *J Clin Oncol* 13:910-913 (1995).
- Boni R, Boni RAH, Steinert H, Burg G, Buck A, Marincek B, Berthold T, Dummer R, Voellmy D, Ballmer B, Vonschulthess GK: Staging of metastatic melanoma by whole-body positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose. *Br J Dermatol* 132:556-562 (1995).
- Brasoveanu LI, Altomonte M, Gloghini A, Fonsatti E, Coral S, Gasparollo A, Montagner R, Cattarossi I, Simonelli C, Cattelan A, Attadia V, Carbone A, Maio M: Expression of protectin (CD59) in human melanoma and its functional role in cell- and complement-mediated cytotoxicity. *Int J Cancer* 61:548-556 (1995).
- Brent PJ, Pang GT: sigma Binding site ligands inhibit cell proliferation in mammary and colon carcinoma cell lines and melanoma cells in culture. *Eur J Pharmacol* 278:151-160 (1995).
- Buttner P, Garbe C, Bertz J, Burg G, Dhoedt B, Drepper H, Guggenmoosholzmann I, Lechner W, Lippold A, Orfanos CE, Peters A, Rassner G, Stadler R, Stroebel W: Primary cutaneous melanoma: Optimized cutoff points of tumor thickness and importance of Clark's level for prognostic classification. *Cancer* 75:2499-2506 (1995).
- Castella AP, Bercher L, Zografos L, Egger E, Herbort CP: Study of the blood-aqueous barrier in choroidal melanoma. *Br J Ophthalmol* 79:354-357 (1995).
- Cilenti L, Toniato E, Ruggiero P, Fusco C, Farina AR, Tiberio A, Hayday AC, Gulino A, Frati L, Martinotti S: Transcriptional modulation of the human intercellular adhesion molecule gene 1 (ICAM-1) by retinoic acid in melanoma cells. *Exp Cell Res* 218:263-270 (1995).
- Ciotti P, Rainero ML, Nicolo G, Spina B, Garre C, Casabona F, Santi PL, Bianchi-Scarra G: Cytokine expression in human primary and metastatic melanoma cells: analysis in fresh bioptic specimens. *Melanoma Res* 5:41-47 (1995).
- Clauser KR, Hall SC, Smith DM, Webb JW, Andrews LE, Tran HM, Epstein LB, Burlingame AL: Rapid mass spectrometric peptide sequencing and mass matching for characterization of human melanoma proteins isolated by two-dimensional PAGE. *Proc Natl Acad Sci USA* 92:5072-5076 (1995).

- Coates AS, Ingvar CI, Petersenschaefter K, Shaw HM, Milton GW, O'Brien CJ, Thompson JF, McCarthy WH: Elective lymph node dissection in patients with primary melanoma of the trunk and limbs treated at the Sydney melanoma unit from 1960 to 1991. *J Amer Coll Surgeons* 180:402-409 (1995).
- Danen EHJ, Jansen KFJ, Vankraats AA, Cornelissen IMHA, Ruiter DJ, Vanmuijen GNP: $\alpha(v)$ -integrins in human melanoma: Gain of $\alpha(v)\beta(3)$ and loss of $\alpha(v)\beta(5)$ are related to tumor progression in situ but not to metastatic capacity of cell lines in nude mice. *Int J Cancer* 61:491-496 (1995).
- Danen EHJ, Vanmuijen GNP, Ruiter DJ: Role of integrins as signal transducing cell adhesion molecules in human cutaneous melanoma. *Cancer Surv* 24:43-65 (1995).
- Deberker D: Aid to diagnosis of melanoma in primary medical care - Doubling of excisions of genuine disease is the important issue. *Br Med J* 310:1328(1995).
- Dehner LP, Wick MR: S100 protein and HMB-45 negative "rhabdoid" malignant melanoma: A totally dedifferentiated malignant melanoma? Reply. *Am J Clin Pathol* 103:773(1995).
- Delmar CB, Green AC: Aid to diagnosis of melanoma in primary medical care - Doubling of excisions of genuine disease is the important issue - Reply. *Br Med J* 310:1328(1995).
- Dereure O, Guillot B, Laurent E, Arnaud B, Guilhou JJ: Ocular malignant melanoma in a patient with van Recklinghausen's disease. *European J Dermatology* 5:117-121 (1995).
- Derooij MJM, Rampen FHJ, Schouten LJ, Neumann HAM: Skin cancer screening focusing on melanoma yields more selective attendance. *Arch Dermatol* 131:422-425 (1995).
- Donin N, Sinai J, Michowitz M, Hiss J, Nordenberg J, Leibovici J: Role of immune response as determinant of tumor progression in function of host age in the B16 melanoma. *Mech Ageing Dev* 80:121-137 (1995).
- Dummer W, Becker JC, Schwaaf A, Leverkus M, Moll T, Brocker EB: Elevated serum levels of interleukin-10 in patients with metastatic malignant melanoma. *Melanoma Res* 5:67-68 (1995).
- Eberle J, Garbe C, Orfanos CE: Identification of genes specifically regulated in human melanoma cells. *Arch Dermatol Res* 287:421-427 (1995).
- Evans RA: Elective lymph node dissection for malignant melanoma: The tumor burden of nodal disease. *Anticancer Res* 15:575-579 (1995).
- Favaro D, Santarosa M, Quaiia M, Spada A, Freschi A, Talmi R, Galligioni E: Soluble intercellular adhesion molecule-1 in melanoma patients treated with liposomes containing muramyl tripeptide. *Eur J Cancer* 31A:1026-1027 (1995).
- Fierlbeck G, Schreiner T, Rassner G: Combination of highly purified human leukocyte interferon α and 13-cis-retinoic acid for the treatment of metastatic melanoma. *Cancer Immunol Immunother* 40:157-164 (1995).
- Foppoli M, Citterio G, Polastri D, Guerrieri R: The feasibility of repetitive courses of high-dose continuous intravenous infusion interleukin-2 and subcutaneous α -interferon with polychemotherapy in advanced malignant melanoma. *Tumori* 81:102-106 (1995).
- Foss AJE, Guille MJ, Occleston NL, Hykin PG, Hungerford JL, Lightman S: The detection of melanoma cells in peripheral blood by reverse transcription polymerase chain reaction. *Br J Cancer* 72:155-159 (1995).
- Frohlich E, Schaumburglever G, Klessen C: Immunocytochemical and immunoelectron microscopic demonstration of cathepsin B in human malignant melanoma. *Br J Dermatol* 132:867-875 (1995).
- Garbe C, Buttner P, Bertz J, Burg G, Dhoedt B, Drepper H, Guggenmoosholzmann I, Lechner W, Lippold A, Orfanos CE, Peters A, Rassner G, Stadler R, Stroebel W: Primary cutaneous melanoma: Identification of prognostic groups and estimation of individual prognosis for 5093 patients. *Cancer* 75:2484-2491 (1995).
- Garbe C, Buttner P, Bertz J, Burg G, Dhoedt B, Drepper H, Guggenmoosholzmann I, Lechner W, Lippold A, Orfanos CE, Peters A, Rassner G, Stadler R, Stroebel W: Primary cutaneous melanoma: Prognostic classification of anatomic location. *Cancer* 75:2492-2498 (1995).
- Gelsleichter L, Gown AM, Zarbo RJ, Wang E, Coltrera MD: p53 and mdm-2 expression in malignant melanoma: An immunocytochemical study of expression of p53, mdm-2, and markers of cell proliferation in primary versus metastatic tumors. *Modern Pathol* 8:530-535 (1995).
- Gold JE, Ross SD, Krellenstein DJ, Larosa F, Malamud SC, Osband ME: Adoptive transfer of *ex vivo* activated memory T-cells with or without cyclophosphamide for advanced metastatic melanoma: Results in 36 patients. *Eur J Cancer* 31A:698-708 (1995).
- Gold JE, Zachary DT, Osband ME: Adoptive transfer of *ex vivo*-activated memory T-cell subsets with cyclophosphamide provides effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma. *Int J Cancer* 61:580-586 (1995).
- Grossniklaus HE, Barron BC, Wilson MW: Murine model of anterior and posterior ocular melanoma. *Curr Eye Res* 14:399-404 (1995).
- Gruis NA, Vandervelden PA, Sandkuijl LA, Prins DE, Weaverfeldhaus J, Kamb A, Bergman W, Frants RR: Homozygotes for CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds. *Nat Genet* 10:351-353 (1995).
- Gruis NA, Weaverfeldhaus J, Liu QY, Frye C, Eeles R, Orlow I, Lacombe L, Poncecastaneda V, Lianes P, Latres E, Skolnick M, Cordoncardo C, Kamb A: Genetic evidence in melanoma and bladder cancers that p16 and p53 function in separate pathways of tumor suppression. *Am J Pathol* 146:1199-1206 (1995).
- Guo HB, Stoffelwagner B, Bierwirth T, Mezger J, Klingmuller D: Clinical significance of serum S100 in metastatic malignant melanoma. *Eur J Cancer* 31A:924-928 (1995).
- Gutman M, Singh RK, Xie KP, Bucana CD, Fidler IJ: Regulation of interleukin-8 expression in human melanoma cells by the organ environment. *Cancer Res* 55:2470-2475 (1995).

- Hahkakemppinen M, Muhonen T, Virolainen M, Jekunen A, Askoseljavaara S, Pyrhonen S: Response of subcutaneous and cutaneous metastases of malignant melanoma to combined cytostatic plus interferon therapy. *Br J Dermatol* 132:973-977 (1995).
- Hamby CV, Mendola CE, Potla L, Stafford G, Backer JM: Differential expression and mutation of NME genes in autologous cultured human melanoma cells with different metastatic potentials. *Biochem Biophys Res Commun* 211:578-585 (1995).
- Hara I, Nguyen H, Takechi Y, Gansbacher B, Chapman PB, Houghton AN: Rejection of mouse melanoma elicited by local secretion of interleukin-2: Implicating macrophages without T cells or natural killer cells in tumor rejection. *Int J Cancer* 61:253-260 (1995).
- Harrison DA, Hodge DO, Bourne WM: Outcome of corneal grafting with donor tissue from eyes with primary choroidal melanomas: A retrospective cohort comparison. *Arch Ophthalmol* 113:753-756 (1995).
- Hedblad MA, Borglund E: Precursor lesion of malignant melanoma in xeroderma pigmentosum: Reflections about solar lentigo as the precursor. *J Am Acad Dermatol* 32:680-681 (1995).
- Helling F, Zhang S, Shang A, Adluri S, Calves M, Koganty R, Longenecker BM, Yao TJ, Oettgen HF, Livingston PO: G(M2)-KLH conjugate vaccine: Increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21. *Cancer Res* 55:2783-2788 (1995).
- Herbst RA, Larson A, Weiss J, Cavenee WK, Hampton GM, Arden KC: A defined region of loss of heterozygosity at 11q23 in cutaneous malignant melanoma. *Cancer Res* 55:2494-2496 (1995).
- Herd RM, Cooper EJ, Hunter JAA, McLaren K, Chetty U, Watson ACH, Gollock J: Cutaneous malignant melanoma. Publicity, screening clinics and survival - The Edinburgh experience 1982-90. *Br J Dermatol* 132:563-570 (1995).
- Herlyn D, Somasundaram R, Zaloudik J, Li W, Jacob L, Harris D, Kieny MP, Ricciardi R, Gonczol E, Sears H, Mastrangelo M: Cloned antigens and anti-idiotypes. *Hybridoma* 14:159-166 (1995).
- Heymann D, Blanchard F, Raher S, Degroote D, Godard A: Modulation of LIF expression in human melanoma cells by Oncostatin M. *Immunol Lett* 46:245-251 (1995).
- Hiraga T, Nakajima T, Ozawa H: Bone resorption induced by a metastatic human melanoma cell line. *Bone* 16:349-356 (1995).
- Hodge WG, Duclos AJ, Rocha G, Anteck E, Baines MG, Corriveau C, Brownstein S, Deschenes J: DNA index and S phase fraction in uveal malignant melanomas. *Br J Ophthalmol* 79:521-526 (1995).
- Holly EA, Aston DA, Cress RD, Ahn DK, Kristiansen JJ: Cutaneous melanoma in women. 1. Exposure to sunlight, ability to tan, and other risk factors related to ultraviolet light. *Am J Epidemiol* 141:923-933 (1995).
- Holly EA, Aston DA, Cress RD, Ahn DK, Kristiansen JJ: Cutaneous melanoma in women. 2. Phenotypic characteristics and other host-related factors. *Am J Epidemiol* 141:934-942 (1995).
- Holly EA, Cress RD, Ahn DK: Cutaneous melanoma in women. 3. Reproductive factors and oral contraceptive use. *Am J Epidemiol* 141:943-950 (1995).
- Iida J, Meijne AML, Spiro RC, Roos E, Furcht LT, Mccarthy JB: Spreading and focal contact formation of human melanoma cells in response to the stimulation of both melanoma-associated proteoglycan (NG2) and $\alpha 4 \beta 1$ integrin. *Cancer Res* 55:2177-2185 (1995).
- Inokuchi J, Usuki S, Jimbo M: Stimulation of glycosphingolipid biosynthesis by L-threo-1-phenyl-2-decanoylamino-1-propanol and its homologs in B16 melanoma cells. *J Biochem Tokyo* 117:766-773 (1995).
- Inoue S, Hasegawa K, Ito S, Ozeki H, Solano F, Jimenez-Cervantes C, Wakamatsu K, Fujita K: Antimelanoma effect of 4-S-cysteaminylcatechol, an activated form of 4-S-cysteaminyphenol. *Cancer Res* 55:2603-2607 (1995).
- Iscovich J, Ackerman C, Andreev H, Peer J, Steinitz R: An epidemiological study of posterior uveal melanoma in Israel, 1961-1989. *Int J Cancer* 61:291-295 (1995).
- Jiang HP, Lin J, Su ZZ, Herlyn M, Kerbel RS, Weissman BE, Welch DR, Fisher PB: The melanoma differentiation-associated gene mda-6, which encodes the cyclin-dependent kinase inhibitor p21, is differentially expressed during growth, differentiation and progression in human melanoma cells. *Oncogene* 10:1855-1864 (1995).
- Johnson TM, Smith JW, Nelson BR, Chang A: Current therapy for cutaneous melanoma. *J Am Acad Dermatol* 32:689-707 (1995).
- Jobb AW, Haines GK, Kies MS, Shields TW: Primary malignant melanoma of the esophagus. *Ann Thorac Surg* 60:217-222 (1995).
- Kageshita T, Hirai S, Kimura T, Hanai N, Ohta S, Ono T: Association between sialyl Lewis(a) expression and tumor progression in melanoma. *Cancer Res* 55:1748-1751 (1995).
- Karakousis CP, Driscoll DL: Prognostic parameters in localized melanoma: Gender versus anatomical location. *Eur J Cancer* 31A:320-324 (1995).
- Kawakami Y, Eliyahu S, Jennings C, Sakaguchi K, Kang XQ, Southwood S, Robbins PF, Sette A, Appella E, Rosenberg SA: Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with *in vivo* tumor regression. *J Immunol* 154:3961-3968 (1995).
- Keeley D: Screening for melanoma risk is misguided. *Br Med J* 310:916(1995).
- Kleeberg UR, Eggermont AM: Twenty-five years of pluridisciplinary approach for melanoma patients. The European Organization on Research and Treatment of Cancer Melanoma Cooperative Group (EORTC-MCG). *Melanoma Res* 5:69-72 (1995).
- Koop S, Macdonald IC, Luzzi K, Schmidt EE, Morris VL, Grattan M, Khokha R, Chambers AF, Groom AC: Fate of melanoma cells entering the microcirculation: Over 80% survive and extravasate. *Cancer Res* 55:2520-2523 (1995).

- Krag DN, Meijer SJ, Weaver DL, Loggie BW, Harlow SP, Tanabe KK, Laughlin EH, Alex JC: Minimal-access surgery for staging of malignant melanoma. *Arch Surg* 130:654-658 (1995).
- Krauss JC, Cameron MJ, Park AN, Forslund K, Chang AE: Efficient transduction of early passage human melanoma to secrete IL-4. *J Immunol Methods* 183:239-250 (1995).
- Kruit WHJ, Goey SH, Calabresi F, Lindemann A, Stahel RA, Poliwoda H, Osterwalder B, Stoter G: Final report of a phase II study of interleukin 2 and interferon α in patients with metastatic melanoma. *Br J Cancer* 71:1319-1321 (1995).
- Lasek W, Wankowicz A, Kuc K, Feleszko W, Golab J, Giermasz A, Wiktorjdrzejczak W, Jakobisiak M: Potentiation of antitumor effects of tumor necrosis factor α and interferon γ by macrophage-colony-stimulating factor in a MmB16 melanoma model in mice. *Cancer Immunol Immunother* 40:315-321 (1995).
- Laskin WB, Knittel DR, Frame JN: S100 protein and HMB-45 negative "rhabdoid" malignant melanoma: A totally dedifferentiated malignant melanoma? *Am J Clin Pathol* 103:772-773 (1995).
- Lee KY, Goedegebuure PS, Linehan DC, Eberlein TJ: Immunoregulatory effects of CD4(+) T helper subsets in human melanoma. *Surgery* 117:365-372 (1995).
- Lehmann F, Marchand M, Hainaut P, Pouillart P, Sastre X, Ikeda H, Boon T, Coulie PG: Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection. *Eur J Immunol* 25:340-347 (1995).
- Licata AG, Wilson LD, Braverman IM, Feldman AM, Kacinski BM: Malignant melanoma and other second cutaneous malignancies in cutaneous T-cell lymphoma: The influence of additional therapy after total skin electron beam radiation. *Arch Dermatol* 131:432-435 (1995).
- Little P, Keefe M, White J: Self screening for risk of melanoma: Validity of self mole counting by patients in a single general practice. *Br Med J* 310:912-916 (1995).
- Logani S, Cho AS, Su LD, Withers HR, Mcbride WH, Hall MO, Lee DA, Milani JK, Straatsma BR: Effects of γ radiation on the OM431 human ocular melanoma cell line. *Exp Eye Res* 60:603-605 (1995).
- Longatto A, Decarvalho LV, Santos GD, Oyafuso MS, Lombardo V, Bortolan J, Neves JI: Cytologic diagnosis of melanoma in serous effusions - A morphologic and immunocytochemical study. *Acta Cytol* 39:481-484 (1995).
- Luyten GPM, Mooy CM, Eijkenboom WMH, Stijnen T, Hellemons LP, Luijder TM, Dejong PTVM: No demonstrated effect of pre-enucleation irradiation on survival of patients with uveal melanoma. *Am J Ophthalmol* 119:786-791 (1995).
- Maass G, Schweighoffer T, Berger M, Schmidt W, Herbst E, Zatloukal K, Buschle M: Tumor vaccines: Effects and fate of IL-2 transfected murine melanoma cells *in vivo*. *Int J Immunopharmacol* 17:65(1995).
- Mackiewicz A, Gorny A, Laciak M, Malicki J, Murawa P, Nowak J, Wiznerowicz M, Hawley RG, Heinrich PC, Rosejohn S: Gene therapy of human melanoma. Immunization of patients with autologous tumor cells admixed with allogeneic melanoma cells secreting interleukin 6 and soluble interleukin 6 receptor. *Hum Gene Ther* 6:805-811 (1995).
- Macneill IB, Elwood JM, Miller D, Mao Y: Trends in mortality from melanoma in Canada and prediction of future rates. *Stat Med* 14:821-839 (1995).
- Marchetti D, Mccutcheon IE, Ross MJ, Nicolson GL: Inverse expression of neurotrophins and neurotrophin receptors at the invasion front of human melanoma brain metastases. *Int J Oncol* 7:87-94 (1995).
- Marghoob AA, Slade J, Kopf AW, Rigel DS, Friedman RJ: The ABCDs of melanoma: Why change? *J Am Acad Dermatol* 32:682-684 (1995).
- Mastrangelo MJ: Current clinical practice: Cutaneous melanoma: How much surgery is enough? *Semin Oncol* 22:R16(1995).
- Masuda T, Watanabe S, Amemiya M, Ishizuka M, Takeuchi T: Inhibitory effect of cytostatin on spontaneous lung metastases of B16-BL6 melanoma cells. *J Antibiot* 48:528-529 (1995).
- Melia J: Early detection of cutaneous malignant melanoma in Britain. *Int J Epidemiol* 24:S39-S44 (1995).
- Melia J, Frost T, Grahambrown R, Hunter J, Marsden A, Duvivier G, Warin AP, White J, Whitehead S, Wroughton M, Ellman R, Chamberlain J: Problems with registration of cutaneous malignant melanoma in England. *Br J Cancer* 72:224-228 (1995).
- Minasian LM, Yao TJ, Steffens TA, Scheinberg DA, Williams L, Riedel E, Houghton AN, Chapman PB: A phase I study of anti-GD3 ganglioside monoclonal antibody R24 and recombinant human macrophage-colony stimulating factor in patients with metastatic melanoma. *Cancer* 75:2251-2257 (1995).
- Mittelman A, Wang XH, Matsumoto K, Ferrone S: Antiantidiotypic response and clinical course of the disease in patients with malignant melanoma immunized with mouse antidiotypic monoclonal antibody MK2-23. *Hybridoma* 14:175-181 (1995).
- Morioka N, Kikumoto Y, Hoon DSB, Morton DL, Irie RF: Cytotoxic T cell recognition of a human melanoma derived peptide with a carboxyl-terminal alanine-proline sequence. *Mol Immunol* 32:573-581 (1995).
- Moynihan GD: The ABCDs of melanoma: Why change? - Reply. *J Am Acad Dermatol* 32:684(1995).
- Naldi L, Locati F, Finazzi G, Barbui T, Cainelli T: Antiphospholipid syndrome associated with immunotherapy for patients with melanoma. *Cancer* 75:2784-2785 (1995).
- Nip J, Rabbani SA, Shibata HR, Brodt P: Coordinated expression of the vitronectin receptor and the urokinase-type plasminogen activator receptor in metastatic melanoma cells. *J Clin Invest* 95:2096-2103 (1995).
- O'Connor TJ, Fujita DJ: Differentiation of B16 murine melanoma cells is associated with an increased level of c-SRC. *Melanoma Res* 5:5-13 (1995).
- Olney RC, Anhalt H, Neely EK, Wilson DM: A quantitative assay for IGF-I and IGF binding protein mRNAs: Expression in malignant melanoma cells. *Mol Cell Endocrinol* 110:213-223 (1995).

- Olsen AC, Fossum B, Kirkin AF, Zeuthen J, Gaudernack G: A human melanoma cell line, recognized by both HLA class I and class II restricted T cells, is capable of initiating both primary and secondary immune responses. *Scand J Immunol* 41:357-364 (1995).
- Oosterhuis JA, Journeedeekorver HG, Kakebeekekemme HM: Transpupillary thermotherapy in choroidal melanomas. *Arch Ophthalmol* 113:693(1995).
- Paglia D, Oran A, Lu C, Kerbel RS, Sauder DN, Mckenzie RC: Expression of leukemia inhibitory factor and interleukin- 11 by human melanoma cell lines: LIF, IL-6, and IL-11 are not coregulated. *J Interferon Cytokine Res* 15:455-460 (1995).
- Palomares T, Bilbao P, Alonsovarona A, Barberaguille E: The addition of interleukin-2 to cyclophosphamide therapy can facilitate tumor growth of B16 melanoma. *Cancer Immunol Immunother* 40:292-298 (1995).
- Pearce RL: Subungual desmoplastic melanoma in an aboriginal woman. *Med J Aust* 162:611-612 (1995).
- Prescher G, Bornfeld N, Friedrichs W, Seeber S, Becher R: Cytogenetics of twelve cases of uveal melanoma and patterns of nonrandom anomalies and isochromosome formation. *Cancer Genet Cytogenet* 80:40-46 (1995).
- Prezioso JA, Hearing VJ, Muller J, Urabe K, Wang N, Gorelik E: Impairment of the melanogenic pathway in B16 melanoma cells transfected with class 1 H-2 genes. *Melanoma Res* 5:15-26 (1995).
- Punt CJA, Tytgat JH, Vanliessum PA, Gerard B: Fotemustine and tamoxifen combination therapy in metastatic malignant melanoma. A phase II study. *Eur J Cancer* 31A:421-422 (1995).
- Rampen FHJ, Casparievanvelsen IJAMG, Vanhuystee BEWL, Kiemeney LALM, Schouten LJ: False-negative findings in skin cancer and melanoma screening. *J Am Acad Dermatol* 33:59-63 (1995).
- Ranade K, Hussussian CJ, Sikorski RS, Varmus HE, Goldstein AM, Tucker MA, Serrano M, Hannon GJ, Beach D, Dracopoli NC: Mutations associated with familial melanoma impair p16(INK4) function. *Nat Genet* 10:114-116 (1995).
- Rennie I: Uveal melanoma: Cell cycles and survival. *Br J Ophthalmol* 79:513-514 (1995).
- Richmond I, Eyden BP, Banerjee SS: Intranodal Langerhans' cell histiocytosis associated with malignant melanoma. *Histopathology* 26:380-382 (1995).
- Robbins PF, Elgamil M, Li YF, Topalian SL, Rivoltini L, Sakaguchi K, Appella E, Kawakami Y, Rosenberg SA: Cloning of a new gene encoding an antigen recognized by melanoma-specific HLA-A24-restricted tumor-infiltrating lymphocytes. *J Immunol* 154:5944-5950 (1995).
- Rosenblum MG, Cheung L, Mujoo K, Murray JL: An antimelanoma immunotoxin containing recombinant human tumor necrosis factor: Tissue disposition, pharmacokinetic, and therapeutic studies in xenograft models. *Cancer Immunol Immunother* 40:322-328 (1995).
- Rummelt V, Folberg R, Woolson RF, Hwang T, Peer J: Relation between the microcirculation architecture and the aggressive behavior of ciliary body melanomas. *Ophthalmology* 102:844-851 (1995).
- Sagebiel RW: Who needs zebras? Comments on desmoplastic melanoma. *J Am Acad Dermatol* 32:800-802 (1995).
- Sarkar S, Flores I, Ron Y, Derosa C, Ozzello L, Pestka S: Injection of irradiated B16 melanoma genetically modified to secrete IFN- α causes regression of an established tumor. *Int J Oncol* 7:17-24 (1995).
- Schadendorf D, Herfordt R, Czarnetzki BM: P-glycoprotein expression in primary and metastatic malignant melanoma. *Br J Dermatol* 132:551-555 (1995).
- Schultz N, Oratz R, Chen DL, Zeleniuchjacquotte A, Abeles G, Bystryjn JC: Effect of DETOX as an adjuvant for melanoma vaccine. *Vaccine* 13:503-508 (1995).
- Schwechheimer K, Zhou LP: HMB45: A specific marker for melanoma metastases in the central nervous system? *Virchows Archiv* 426:351-353 (1995).
- Sensi M, Traversari C, Radrizzani M, Salvi S, Maccalli C, Mortarini R, Rivoltini L, Farina C, Nicolini G, Wolfel T, Brichard V, Boon T, Bordignon C, Anichini A, Parmiani G: Cytotoxic T-lymphocyte clones from different patients display limited T-cell-receptor variable-region gene usage in HLA-A2-restricted recognition of the melanoma antigen Melan-A/MART-1. *Proc Natl Acad Sci USA* 92:5674-5678 (1995).
- Shrayer D, Bogaars H, Hearing VJ, Maizel A, Wanebo H: Further characterization of a clinically relevant model of melanoma metastasis and an effective vaccine. *Cancer Immunol Immunother* 40:277-282 (1995).
- Shumate CR, Urist MM, Maddox WA: Melanoma recurrence surveillance: Patient or physician based? *Ann Surg* 221:566-571 (1995).
- Silvani A, Ferrari G, Paonessa G, Toniatti C, Parmiani G, Colombo MP: Down-regulation of interleukin 6 receptor α chain in interleukin 6 transduced melanoma cells causes selective resistance to interleukin 6 but not to oncostatin M. *Cancer Res* 55:2200-2205 (1995).
- Sivam GP, Martin PJ, Reisfeld RA, Mueller BM: Therapeutic efficacy of a doxorubicin immunoconjugate in a preclinical model of spontaneous metastatic human melanoma. *Cancer Res* 55:2352-2356 (1995).
- Skelton HG, Smith KJ, Laskin WB, Mccarthy WF, Gagnier JM, Graham JH, Lupton GP: Desmoplastic malignant melanoma. *J Am Acad Dermatol* 32:717-725 (1995).
- Spruss T, Bernhardt G, Schonenberger H, Schiess W: Hyaluronidase significantly enhances the efficacy of regional vinblastine chemotherapy of malignant melanoma. *J Cancer Res Clin Oncol* 121:193-202 (1995).
- Stanganelli I, Raccagni AA, Baldassari L, Calista D, Serafini M, Bucchi L: Analysis of Breslow tumor thickness distribution of skin melanoma in the Italian region of Romagna, 1986-1991. *Tumori* 80:416-421 (1994).
- Steinert HC, Boni RAH, Buck A, Boni R, Berthold T, Marincek B, Burg G, Vonschulthess GK: Malignant melanoma: Staging with whole-body positron emission tomography and 2-[F-18]-fluoro-2-deoxy-D-glucose. *Radiology* 195:705-709 (1995).
- Stern JB: Precursor lesion of malignant melanoma in xeroderma pigmentosum: Reflections about solar lentigo as the precursor - Reply. *J Am Acad Dermatol* 32:681-682 (1995).

- Swerdlow AJ, English JSC, Qiao Z: The risk of melanoma in patients with congenital nevi: A cohort study. *J Am Acad Dermatol* 32:595-599 (1995).
- Swerdlow AJ, Storm HH, Sasieni PD: Risks of second primary malignancy in patients with cutaneous and ocular melanoma in Denmark, 1943-1989. *Int J Cancer* 61:773-779 (1995).
- Timar J, Bazaz R, Kimler V, Haddad M, Tang DG, Robertson D, Tovari J, Taylor JD, Honn KV: Immunomorphological characterization and effects of 12-(S)- HETE on a dynamic intracellular pool of the α (IIb) β (3)-integrin in melanoma cells. *J Cell Sci* 108:2175-2186 (1995).
- Travers RL, Sober AJ, Berwick M, Mihm MC, Barnhill RL, Duncan LM: Increased thickness of pregnancy-associated melanoma. *Br J Dermatol* 132:876-883 (1995).
- Tufto I, Rofstad EK: Transient perfusion in human melanoma xenografts. *Br J Cancer* 71:789-793 (1995).
- Tufto I, Rofstad EK: Interstitial fluid pressure in human melanoma xenografts -Relationship to fractional tumor water content, tumor size, and tumor volume-doubling time. *Acta Oncol* 34:361-365 (1995).
- Tyler DS, Francis GM, Frederick M, Tran AH, Ordonez NG, Smith JL, Eton O, Ross M, Grimm EA: Interleukin-1 production in tumor cells of human melanoma surgical specimens. *J Interferon Cytokine Res* 15:331-340 (1995).
- Vandenbrule FA, Buicu C, Baldet M, Sobel ME, Cooper DNW, Marschal P, Castronovo V: Galectin-1 modulates human melanoma cell adhesion to laminin. *Biochem Biophys Res Commun* 209:760-767 (1995).
- Vanmuijen GNP, Danen EHJ, Veerkamp JH, Ruiten DJ, Lesley J, Vandenheuvel LPWJ: Glycoconjugate profile and CD44 expression in human melanoma cell lines with different metastatic capacity. *Int J Cancer* 61:241-248 (1995).
- Veiga SS, Chammas R, Cella N, Brentani RR: Glycosylation of β -1 integrins in B16-F10 mouse melanoma cells as determinant of differential binding and acquisition of biological activity. *Int J Cancer* 61:420-424 (1995).
- Verhaegh MEJM, Sanders CJG, Arends JW, Neumann HAM: Expression of the apoptosis-suppressing protein Bcl-2 in non-melanoma skin cancer. *Br J Dermatol* 132:740-744 (1995).
- Verschraegen CF, Mendoza JT, Kozielski AJ, Giovanella BC: Modulation of the response to chemotherapy in a human melanoma clone by the site of growth in the nude mouse. *Anticancer Res* 15:9-11 (1995).
- Vuoristo MS, Grohn P, Kellokumpulehtinen P, Turunen M, Joensuu H, Kumpulainen E, Korpela M, Tiisanen K, Nevantaus A: Interimittent interferon and polychemotherapy in metastatic melanoma. *J Cancer Res Clin Oncol* 121:175-180 (1995).
- Wagner SN, Ockenfels HM, Wagner C, Hofler H, Goos M: Ras gene mutations: A rare event in nonmetastatic primary malignant melanoma. *J Invest Dermatol* 104:868-871 (1995).
- Wakeling WF, Souberbielle BE, Bennett DC: Detection of a human DNA sequence correlated with melanocyte-like differentiation and tumour suppression after transfection into murine melanoma cells. *Melanoma Res* 5:27-40 (1995).
- Walsh P, Dorner A, Duke RC, Su LJ, Glode LM: Macrophage colony-stimulating factor complementary DNA: A candidate for gene therapy in metastatic melanoma. *J Nat Cancer Inst* 87:809-816 (1995).
- Wellbrock C, Lammers R, Ullrich A, Schartl M: Association between the melanoma-inducing receptor tyrosine kinase Xmrk and src family tyrosine kinases in *Xiphophorus*. *Oncogene* 10:2135-2143 (1995).
- Westerdahl J, Olsson H, Masback A, Ingvar C, Jonsson N: Is the use of sunscreens a risk factor for malignant melanoma? *Melanoma Res* 5:59-65 (1995).
- White TK, Zhu QA, Tanzer ML: Cell surface calreticulin is a putative mannoside lectin which triggers mouse melanoma cell spreading. *J Biol Chem* 270:15926-15929 (1995).
- Yamasaki S, Okino T, Chakraborty NG, Adkisson WO, Sampieri A, Padula SJ, Mauri F, Mukherji B: Presentation of synthetic peptide antigen encoded by the MAGE-1 gene by granulocyte macrophage-colony-stimulating-factor-cultured macrophages from HLA-A1 melanoma patients. *Cancer Immunol Immunother* 40:268-271 (1995).
- Zolzer F, Streffer C: Cell cycle-dependent expression of Ki-67 antigen in human melanoma cells subjected to irradiation and/or hyperthermia. *Radiat Res* 143:98-101 (1995).

MSH, POMC, GROWTH FACTORS & RECEPTORS

- Bagutti C, Oestreicher M, Siegrist W, Oberholzer M, Eberle AN: α -MSH receptor autoradiography on mouse and human melanoma tissue sections and biopsies. *J Recept Signal Transduct Res* 15:427-442 (1995).
- Balm PHM, Hovens MLM, Bonga SEW: Endorphin and MSH in concert form the corticotropic principle released by tilapia (*Oreochromis mossambicus*, Teleostei) melanotropes. *Peptides* 16:463-469 (1995).
- Brett PM, Curtis D, Robertson MM, Gurling HMD: The genetic susceptibility to Gilles de la Tourette Syndrome in a large multiple affected British kindred: Linkage analysis excludes a role for the genes coding for dopamine D1, D2, D3, D4, D5 receptors, dopamine β hydroxylase, tyrosinase, and tyrosine hydroxylase. *Biol Psychiatry* 37:533-540 (1995).
- Carrel S, Hartmann F, Salvi S, Albrecht H, Schreyer M, Rimoldi D: Expression of type A and B tumor necrosis factor (TNF) receptors on melanoma cells can be regulated by dbc-AMP and IFN γ . *Int J Cancer* 62:76-83 (1995).
- Chin Y, Janssens J, Bleus J, Vandevijver C, Zhang JW, Raus J: T cell receptor V β usage of tumor infiltrating lymphocyte lines cloned from human breast tumor and melanoma. *Int J Oncol* 7:147-153 (1995).
- Chlubadetapia J, Bagutti C, Wikberg JS, Chhajlani V, Eberle AN: Stable expression of the human MSH receptor in a mouse melanoma cell line. *J Recept Signal Transduct Res* 15:43-53 (1995).

- ☞ Cohen T, Gitaygoren H, Sharon R, Shibuya M, Halaban R, Levi BZ, Neufeld G: VEGF(121), a vascular endothelial growth factor (VEGF) isoform lacking heparin binding ability, requires cell- surface heparan sulfates for efficient binding to the VEGF receptors of human melanoma cells. *J Biol Chem* 270:11322-11326 (1995).
- Coleman A, Robertson G, Lugo TG: Growth control by tumor suppressors in malignant melanoma. *Receptor* 5:9-19 (1995).
- Davol P, Beitz JG, Frackelton AR: Autocrine down-regulation of basic fibroblast growth factor receptors causes mitotoxin resistance in a human melanoma cell line. *J Invest Dermatol* 104:916-921 (1995).
- ☞ Dean AD, Frost-Mason SK: Effects of melanocyte-stimulating hormone on wild-type and white axolotl neural crest cells. *Biochem Biophys Res Commun* 210:239-245 (1995).
- Dewildt DJ, Kasbergen CM, Versteeg DHG: Effect of $\gamma(2)$ -melanocyte-stimulating hormone on cerebral blood flow in rats. *J Cardiovasc Pharmacol* 25:898-905 (1995).
- Drozdz R, Eberle AN: Binding sites for melanin-concentrating hormone (MCH) in brain synaptosomes and membranes from peripheral tissues identified with highly tritiated MCH. *J Recept Signal Transduct Res* 15:487-502 (1995).
- Dyer JK, Philipsen HLA, Tonnaer JADM, Hermkens PHH, Haynes LW: Melanocortin analogue Org2766 binds to rat Schwann cells, upregulates NGF low-affinity receptor p75, and releases neurotrophic activity. *Peptides* 16:515-522 (1995).
- ☞ Easty DJ, Guthrie BA, Maung K, Farr CJ, Lindberg RA, Toso RJ, Herlyn M, Bennett DC: Protein B61 as a new growth factor: Expression of B61 and up-regulation of its receptor epithelial cell kinase during melanoma progression. *Cancer Res* 55:2528-2532 (1995).
- Facchinetti F, Bernasconi S, Iughetti L, Genazzani AD, Ghizzoni L, Genazzani AR: Changes in dopaminergic control of circulating melanocyte-stimulating hormone-related peptides at puberty. *Pediatr Res* 38:91-94 (1995).
- Fischer EG, Ruf W, Mueller BM: Tissue factor-initiated thrombin generation activates the signaling thrombin receptor on malignant melanoma cells. *Cancer Res* 55:1629-1632 (1995).
- Francis K, Baker BI: Developmental changes in melanin-concentrating hormone in *Rana temporaria*. *Gen Comp Endocrinol* 98:157-165 (1995).
- Garratt PJ, Jones R, Tocher DA, Sugden D: Mapping the melatonin receptor .3. Design and synthesis of melatonin agonists and antagonists derived from 2-phenyltryptamines. *J Med Chem* 38:1132-1139 (1995).
- Griffond B, Deray A, Nguyen NU, Colard C, Fellmann D: The synthesis of melanin-concentrating hormone is stimulated by ventromedial hypothalamic lesions in the rat lateral hypothalamus: A time-course study. *Neuropeptides* 28:267-275 (1995).
- Groneveld D, Eckhardt ERM, Coenen AJM, Martens GJM, Balm PHM, Bonga SEW: Expression of tilapia prepro-melanin-concentrating hormone mRNA in hypothalamic and neurohypophysial cells. *J Molecular Endocrinol* 14:199-207 (1995).
- ☞ Haskelluevano C, Shenderovich MD, Sharma SD, Nikiforovich GV, Hadley ME, Hruby VJ: Design, synthesis, biology, and conformations of bicyclic α -melanotropin analogues. *J Med Chem* 38:1736-1750 (1995).
- Hervieu G, Nahon JL: Pro-melanin concentrating hormone messenger ribonucleic acid and peptides expression in peripheral tissues of the rat. *Neuroendocrinology* 61:348-364 (1995).
- Hesselgesser J, Chitnis CE, Miller LH, Yansura DG, Simmons LC, Fairbrother WJ, Kotts C, Wirth C, Gilleceastro BL, Horuk R: A mutant of melanoma growth stimulating activity does not activate neutrophils but blocks erythrocyte invasion by malaria. *J Biol Chem* 270:11472-11476 (1995).
- ☞ Hill HZ, Hill GJ, Cieszka K, Azure M, Chowdhary I, Sayre RM: A multitherapy resistance factor from melanoma reveals that killing by near UV is different from genotoxic agents. *Photochem Photobiol* 61:479-483 (1995).
- Kawai S, Yahata N, Nishida S, Nagai K, Mizushima Y: Dehydroepiandrosterone inhibits B16 mouse melanoma cell growth by induction of differentiation. *Anticancer Res* 15:427-431 (1995).
- Kim Y, Carpenter AM, Gregg KJ, Shahnaz Z, Carr JA: Diurnal variation in α -melanocyte-stimulating hormone content of various brain regions and plasma of the Texas toad, *Bufo speciosus*. *Gen Comp Endocrinol* 98:50-56 (1995).
- Kosano H, Setogawa T, Kobayashi K, Nishigori H: Pyrroloquinoline quinone (PQQ) inhibits the expression of tyrosinase mRNA by α -melanocyte stimulating hormone in murine B16 melanoma cells. *Life Sci* 56:1707-1713 (1995).
- Lamacz M, Garnier M, Hery F, Tonon MC, Vaudry H: Adrenergic control of α -melanocyte-stimulating hormone release in frog pituitary is mediated by both β - and a nonconventional $\alpha(2)$ -subtype of adrenoreceptors. *Neuroendocrinology* 61:430-436 (1995).
- Lincoln GA, Baker BI: Seasonal and photoperiod-induced changes in the secretion of α -melanocyte-stimulating hormone in Soay sheep: Temporal relationships with changes in β -endorphin, prolactin, follicle-stimulating hormone, activity of the gonads and growth of wool and horns. *J Endocrinol* 144:471-481 (1995).
- Miwa H, Gantz I, Konda Y, Shimoto Y, Yamada T: Structural determinants of the melanocortin peptides required for activation of melanocortin-3 and melanocortin-4 receptors. *J Pharmacol Exp Ther* 273:367-372 (1995).
- Nozaki M, Takahashi A, Amemiya Y, Kawauchi H, Sower SA: Distribution of lamprey adrenocorticotropin and melanotropins in the pituitary of the adult sea lamprey, *Petromyzon marinus*. *Gen Comp Endocrinol* 98:147-156 (1995).
- Prusis P, Frandberg PA, Muceniece R, Kalvinsh I, Wikberg JES: A three dimensional model for the interaction of MSH with the melanocortin-1 receptor. *Biochem Biophys Res Commun* 210:205-210 (1995).

- Rogivue C, Car BD, Allmanniselin I, Zwahlen RD, Walz A: Bovine melanoma growth stimulatory activity: A new monocyte-macrophage derived cytokine of the IL-8 family - Partial structure, function, and expression in acute pulmonary inflammation. *Lab Invest* 72:689-695 (1995).
- Shimizu H, Tanaka Y, Sato N, Mori M: α -Melanocyte-stimulating hormone (MSH) inhibits insulin secretion in HIT-T 15 cells. *Peptides* 16:605-608 (1995).
- Siegrist W, Eberle AN: Melanocortins and their implication in melanoma. *Trends Endocrinol Metab* 6:115-120 (1995).
- Siegrist W, Sauter P, Eberle AN: A selective protein kinase C inhibitor (CGP 41251) positively and negatively modulates melanoma cell MSH receptors. *J Recept Signal Transduct Res* 15:283-296 (1995).
- Vanstrien FJC, Galas L, Jenks BG, Roubos EW: Differential acetylation of pro-opiomelanocortin-derived peptides in the pituitary gland of *Xenopus laevis* in relation to background adaptation. *J Endocrinol* 146:159-167 (1995).

TYROSINASE, TYROSINASE RELATED PROTEINS & MOLECULAR BIOLOGY

- Bassi MT, Schiaffino MV, Renieri A, Denigris F, Galli L, Bruttini M, Gebbia M, Bergen AAB, Lewis RA, Ballabio A: Cloning of the gene for ocular albinism type 1 from the distal short arm of the X chromosome. *Nat Genet* 10:13-19 (1995).
- Brey PT, Ahmed A, Lee WJ, Ashida M, Lehane MJ: Tyrosinase-type prophenoloxidase distribution in the alimentary canal of strains of *Anopheles gambiae* refractory and susceptible to Plasmodium infection. *Exp Parasitol* 80:654-664 (1995).
- Cooksey CJ, Land EJ, Ramsden CA, Riley PA: Tyrosinase-mediated cytotoxicity of 4-substituted phenols: Quantitative structure-thiol-reactivity relationships of the derived o-quinones. *Anti-Cancer Drug Des* 10:119-129 (1995).
- Deng Q, Dong SJ: Construction of a tyrosinase-based biosensor in pure organic phase. *Anal Chem* 67:1357-1360 (1995).
- Ellis JP, Gray A, Richards F: Oculocutaneous albinism and bruising in two sisters - Probable Hermansky-Pudlak syndrome. *J R Soc Med* 88:P293-P294 (1995).
- Falikkorenstein TC, Holmes SA, Borochowitz Z, Levin A, Rosenmann A, Spritz RA: DNA-based carrier detection and prenatal diagnosis of tyrosinase-negative oculocutaneous albinism (OCA1A). *Prenat Diagn* 15:345-349 (1995).
- Ferry WL, Hustad CM, Swing DA, Jenkins NA, Copeland NG: A transgenic mouse assay for agouti protein activity. *Genetics* 140:267-274 (1995).
- Funayama M, Arakawa H, Yamamoto R, Nishino T, Shin T, Murao S: Effects of α - and β -arbutin on activity of tyrosinases from mushroom and mouse melanoma. *Biosci Biotechnol Biochem* 59:143-144 (1995).
- Gross A, Kunze J, Maier RF, Stoltenburgdidinger G, Grimmer I, Obladen R: Autosomal-recessive neural crest syndrome with albinism, black lock, cell migration disorder of the neurocytes of the gut, and deafness: ABCD syndrome. *Am J Med Genet* 56:322-326 (1995).
- Hu XY, Leng ZZ: Determination of cyanide using a tyrosinase amperometric biosensor with catechol as substrate. *Analyst* 120:1555-1557 (1995).
- Hustad CM, Perry WL, Siracusa LD, Raspberry C, Cobb L, Cattanauch BM, Kovatch R, Copeland NG, Jenkins NA: Molecular genetic characterization of six recessive viable alleles of the mouse agouti locus. *Genetics* 140:255-265 (1995).
- Jimenez-Cervantes C, Garcia-Borrón JC, Lozano JA, Solano F: Effect of detergents and endogenous lipids on the activity and properties of tyrosinase and its related proteins. *Bba-Gen Subjects* 1243:421-430 (1995).
- Klebig ML, Wilkinson JE, Geisler JG, Woychik RP: Ectopic expression of the agouti gene in transgenic mice causes obesity, features of type II diabetes, and yellow fur. *Proc Natl Acad Sci USA* 92:4728-4732 (1995).
- Lee ST, Nicholls RD, Jong MTC, Fukai K, Spritz RA: Organization and sequence of the human P gene and identification of a new family of transport proteins. *Genomics* 26:354-363 (1995).
- Lookingbill DP, Lookingbill GL, Leppard B: Actinic damage and skin cancer in albinos in northern Tanzania: Findings in 164 patients enrolled in an outreach skin care program. *J Am Acad Dermatol* 32:653-658 (1995).
- Manne J, Argeson AC, Siracusa LD: Mechanisms for the pleiotropic effects of the agouti gene. *Proc Natl Acad Sci USA* 92:4721-4724 (1995).
- Miura I, Okumoto H, Makino K, Nakata A, Nishioka M: Analysis of the tyrosinase gene of the Japanese pond frog, *Kana nigromaculata*: Cloning and nucleotide sequence of the genomic DNA containing the tyrosinase gene and its flanking regions. *Jpn J Genet* 70:79-92 (1995).
- Reish O, Townsend D, Berry SA, Tsai MY, King RA: Tyrosinase inhibition due to interaction of homocyst(e)ine with copper: The mechanism for reversible hypopigmentation in homocystinuria due to cystathionine β -synthase deficiency. *Am J Hum Genet* 57:127-132 (1995).
- Schiaffino MV, Bassi MT, Rugarli EI, Renieri A, Galli L, Ballabio A: Cloning of a human homologue of the *Xenopus laevis* APX gene from the ocular albinism type 1 critical region. *Hum Mol Genet* 4:373-382 (1995).
- Schnur RE, Wick PA: Intragenic TaqI restriction fragment length polymorphism (RFLP) in C1CN4, between the loci for X-linked ocular albinism (OA1) and microphthalmia with linear skin defects syndrome (MLS). *Hum Genet* 95:594-595 (1995).
- Siracusa LD, Washburn LL, Swing DA, Argeson AC, Jenkins NA, Copeland NG: Hypervariable yellow (A^{hvy}), a new murine agouti mutation: A^{hvy} displays the largest variation in coat color phenotypes of all known agouti alleles. *J Hered* 86:121-128 (1995).

- ☞ Spritz RA, Fukai K, Holmes SA, Luande J: Frequent intragenic deletion of the P gene in Tanzanian patients with type II oculocutaneous albinism (OCA2). *Am J Hum Genet* 56:1320-1323 (1995).
- Visseren MJW, Vanelsas A, Vandervoort EIH, Rensing ME, Kast WM, Schrier PI, Melief CJM: CTL specific for the tyrosinase autoantigen can be induced from healthy donor blood to lyse melanoma cells. *J Immunol* 154:3991-3998 (1995).
- Wang J, Chen QA: Microfabricated phenol biosensors based on screen printing of tyrosinase containing carbon ink. *Anal Lett* 28:1131-1142 (1995).
- Ward KA, Moss C, Sanders DSA: Human piebaldism: Relationship between phenotype and site of kit gene mutation. *Br J Dermatol* 132:929-935 (1995).
- Zemel MB, Kim JH, Woychik RP, Michaud EJ, Kadwell SH, Patel IR, Wilkison WO: Agouti regulation of intracellular calcium: Role in the insulin resistance of viable yellow mice. *Proc Natl Acad Sci USA* 92:4733-4737 (1995).

MISCELLANEOUS

- Cinalli G: Melanotic neuroectodermal skull tumor. *J Neurosurg* 82:910(1995).
- Conlee JW, Bennett ML, Creel DJ: Differential effects of gentamicin on the distribution of cochlear function in albino and pigmented guinea pigs. *Acta Oto-Laryngol* 115:367-374 (1995).
- George JC, Edwards MK, Jakacki RI, Khoduffin J: Melanotic neuroectodermal tumor of infancy. *Amer J Neuroradiol* 16:1273-1275 (1995).
- Gonzalez VH, Hu LK, Theodossiadis PG, Flotte TJ, Gragoudas ES, Young LHY: Photodynamic therapy of pigmented choroidal melanomas. *Invest Ophthalmol Visual Sci* 36:871-878 (1995).
- Haddad G, Haddad JG, Kaplan FS: Severe symptomatic osteopenia in a man with pigmented micronodular adrenal hyperplasia. *Clin Orthop* 220-223 (1995).
- Hoshino S, Takahashi H: Melanotic neuroectodermal skull tumor - Response. *J Neurosurg* 82:910-911 (1995).
- ☞ Martha GN, Milos NC: Confrontation of developing melanophore bars of dark and white axolotls with endogenous dark-embryo mannose-binding lectin correlates with melanophore bar disruption. *Pigm Cell Res* 8:66-74 (1995).
- ☞ McLean DI, Gallagher RP: "Sunburn" freckles, cafe-au-lait macules, and other pigmented lesions of schoolchildren: The Vancouver Mole Study. *J Am Acad Dermatol* 32:565-570 (1995).
- Sahn EE, Grine RC: A pigmented paraspinal plaque in an infant - Congenital smooth-muscle hamartoma. *Arch Dermatol* 131:609(1995).
- Vinores SA, Henderer JD, Mahlow J, Chiu C, Derevjani NL, Laroche W, Csaky C, Campochiaro PA: Isoforms of platelet-derived growth factor and its receptors in epiretinal membranes: Immunolocalization to retinal pigmented epithelial cells. *Exp Eye Res* 60:607-619 (1995).